US20050210535A1 - Toxoplasma gondii apical membrane antigen-1 - Google Patents
Toxoplasma gondii apical membrane antigen-1 Download PDFInfo
- Publication number
- US20050210535A1 US20050210535A1 US11/089,047 US8904705A US2005210535A1 US 20050210535 A1 US20050210535 A1 US 20050210535A1 US 8904705 A US8904705 A US 8904705A US 2005210535 A1 US2005210535 A1 US 2005210535A1
- Authority
- US
- United States
- Prior art keywords
- tgama
- polypeptide
- toxoplasma
- antibody
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101900194736 Toxoplasma gondii Apical membrane antigen 1 Proteins 0.000 title description 2
- 101000930553 Toxoplasma gondii (strain ATCC 50861 / VEG) Apical membrane antigen 1 Proteins 0.000 claims abstract description 184
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 165
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 153
- 229920001184 polypeptide Polymers 0.000 claims abstract description 133
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 49
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 46
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 46
- 239000012634 fragment Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 39
- 229960005486 vaccine Drugs 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 244000045947 parasite Species 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 241000223996 Toxoplasma Species 0.000 claims description 37
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 206010057179 Toxoplasma infections Diseases 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 16
- 230000003053 immunization Effects 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 230000009261 transgenic effect Effects 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 230000000890 antigenic effect Effects 0.000 claims description 14
- 241000223997 Toxoplasma gondii Species 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 230000003302 anti-idiotype Effects 0.000 claims description 3
- 201000005485 Toxoplasmosis Diseases 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 72
- 108090000623 proteins and genes Proteins 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 21
- 210000000059 tachyzoite Anatomy 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000001262 western blot Methods 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000002788 anti-peptide Effects 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 101710203310 Apical membrane antigen 1 Proteins 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 241000238631 Hexapoda Species 0.000 description 10
- 239000003599 detergent Substances 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 7
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229920004929 Triton X-114 Polymers 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000000638 solvent extraction Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101710139410 1-phosphatidylinositol phosphodiesterase Proteins 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 201000004792 malaria Diseases 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- -1 antibodies Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010008177 Fd immunoglobulins Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001938 anti-toxoplasmal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000010820 immunofluorescence microscopy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 3
- 229960000611 pyrimethamine Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004306 sulfadiazine Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010058352 Plasmodium apical membrane antigen I Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- NAPNOSFRRMHNBJ-UHFFFAOYSA-N Arprinocid Chemical compound C1=NC=2C(N)=NC=NC=2N1CC1=C(F)C=CC=C1Cl NAPNOSFRRMHNBJ-UHFFFAOYSA-N 0.000 description 1
- 101000730655 Bacillus cereus 1-phosphatidylinositol phosphodiesterase Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101100056797 Canis lupus familiaris SAG gene Proteins 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100532512 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAG1 gene Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229950002343 arprinocid Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 1
- 229960003159 atovaquone Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000061 bradyzoite Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003126 immunogold labeling Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/012—Coccidia antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to TgAMA-1, and TgAMA-1-based animal and human vaccines for toxoplasmosis.
- Toxoplasmosis is among the most common parasitic diseases of man. Serosurveys suggest prevalence rates as high as 70-90% in many areas of both the developing and developed world. Between 10-45% of Americans become infected at some point in their lives. An infection in an individual with a competent immune system generally has minor or no symptoms. The infection tends to be self-limiting, with the individual's immune system controlling and eliminating most of the parasites. Some parasites remain in bradyzoite form following acute infection and will be present in cysts in the central nervous system and muscle throughout the remainder of the individual's life.
- toxoplasma infection can cause mental retardation, visual defects, and death.
- Toxoplasma infection can cause neurological damage, ocular lesions and death in adults with compromised immune systems, a group which includes for example individuals with HIV infection or patients undergoing immune-suppressive treatment for cancer.
- Acute toxoplasmosis can be difficult to treat.
- Sulfadiazine/pyramethamine is a regimen of choice, although side effects serious enough to warrant discontinuation of treatment are common.
- the toxic and potentially teratogenic effects of this regimen make management of the pregnant woman particularly problematic.
- AIDS patients require lifelong suppressive therapy to prevent relapse, and a many as one third of the patients receiving suppressive sulfadiazine/pyrimethamine therapy cannot tolerate the adverse side effects. For those who can tolerate the drugs, relapse occurs frequently.
- Pyrimethamine/clindamycin is a useful alternative therapy in AIDS patients who suffer an unusually high frequency of side effects from sulfa drugs. Unfortunately, this alternative combination can also cause considerable toxicity and is less effective at preventing relapse.
- Prevention of transmission through vaccination would be preferable to treatment, particularly for pregnant women and the immunocompromised.
- TgAMA-1 polypeptide molecules are provided.
- the TgAMA-1 polypeptide molecules include antigenic fragments of the polypeptide sequence set forth as amino acids SEQ ID NO:1.
- fusion proteins are provided that include the foregoing antigenic polypeptide.
- isolated TgAMA-1 nucleic acid molecules are provided.
- the TgAMA-1 nucleic acid molecules are selected from the group consisting of a fragment of the nucleotide sequence set forth as nucleotides 1-2507 of SEQ ID NO: 2 between 12 and 2506 nucleotides in length, and complements of (a), wherein the fragment encodes the foregoing isolated TgAMA-1 polypeptide.
- expression vectors include the isolated foregoing TgAMA-1 nucleic acid molecule operably linked to a promoter.
- expression vectors include an isolated nucleic acid molecule of SEQ ID NO: 2. operably linked to a promoter.
- host cells transformed or transfected with the aforementioned expression vectors are provided.
- the host cell is an insect cell.
- the insect cell is a High FiveTM cell.
- a transgenic non-human animal that includes the foregoing expression vector are provided.
- the transgenic non-human animal expresses a variable level of TgAMA-1.
- the transgenic non-human animal expresses an antigenic fragment of SEQ ID NO: 1.
- the transgenic non-human animal is a mammal.
- the transgenic non-human animal is a bovine.
- vaccine compositions include the foregoing isolated TgAMA-1 polypeptide and an adjuvant.
- vaccine compositions include TgAMA-1 or a functionally active variant thereof, and an adjuvant.
- the vaccine is a proteosome vaccine.
- the adjuvant is selected from the group consisting of: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-analyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-analanine-2-( 1′-2′dipalmitoyl-sn-glycero-3-hydroxyphosphroyloxy)-ethylamine, monophosphoryl lipid A; saponins (QS21; DQS21);
- methods for immunizing a subject include administering to the subject an effective amount for immunizing the subject, of the foregoing vaccines.
- the subject is a mammal.
- the subject is a human.
- the subject is at risk of infection from Toxoplasma gondii.
- the subject is a mammal.
- the subject is a human.
- TgAMA-1 binding polypeptides that selectively bind to the foregoing isolated TgAMA-1 polypeptide are provided.
- the TgAMA-1 binding polypeptide is an antibody or antigen-binding fragment of an antibody.
- the antibody or antigen-binding fragment specifically binds to a region comprising about 12 or more cysteine residues of the forgoing isolated TgAMA-1 polypeptide.
- the binding polypeptide blocks entry of Toxoplasma parasite into a cell.
- the TgAMA-1 binding polypeptide is a monoclonal antibody.
- the TgAMA-1 binding polypeptide is a humanized monoclonal antibody.
- anti-idiotype antibodies that selectively bind to the TgAMA-1 binding polypeptides are provided.
- methods for treating a toxoplasma infection include administering to a subject in need of such treatment, an effective amount of the foregoing TgAMA-1 binding polypeptides to treat the toxoplasma infection.
- the TgAMA-1 binding polypeptide blocks the entry of Toxoplasma parasite into a cell.
- the subject is a mammal. In certain embodiments, the subject is a human.
- methods for reducing the likelihood of a toxoplasma infection include administering to a subject in need of such treatment, an effective amount of a foregoing TgAMA-1 binding polypeptide to reduce the likelihood of toxoplasma infection.
- the TgAMA-1 binding polypeptide blocks the entry of Toxoplasma parasite into a cell.
- the subject is a mammal. In certain embodiments, the subject is a human.
- TgAMA-1 a Toxoplasma gondii tachyzoite protein termed TgAMA-1.
- TgAMA-1 is relatively homologous to the extensively studied apical membrane antigen-1 (AMA-1) family of proteins of malaria parasites.
- AMA-1 apical membrane antigen-1 family of proteins of malaria parasites.
- passive immunization with polyclonal antibodies against AMA-1, or immmunization with native or recombinant renatured AMA-1 protect against parasite challenge; AMA-1 is currently under investigation as a vaccine candidate for human malaria.
- the antigenicity of malarial AMA-1 resides in its extracellular domain, with which TgAMA-1 shows a high degree of structural conservation.
- the present invention relates to the use of recombinant TgAMA-1 and its extracellular domain as vaccines for toxoplasmosis.
- the efficacy of TgAMA-1 as a vaccine is readily confirmed by administering TgAMA-1 and/or vaccine formulations comprising TgAMA-1 to test animals, such as mice.
- Cats and sheep important animal reservoirs of Toxoplasmosis are also readily tested to confirm the vaccine potential of TgAMA-1, as well as ultimately, humans.
- TgAMA-1 means human Toxoplasma gondii apical membrane antigen-1.
- TgAMA-1 molecules includes TgAMA-1 polypeptides, TgAMA-1 nucleic acids, and polypeptides, such as antibodies, that bind to TgAMA-1 polypeptides described herein.
- a “subject” shall mean a human or vertebrate animal including but not limited to a dog, cat, horse, cow, pig, sheep, goat, non-human primate (e.g. monkey), rabbit, rat, mouse, and bird.
- the term “subject” also includes cells collected from a human or animal, for example, blood collected for purposes such as, but not limited to, transfusions.
- the term “cell” means a cell capable of being infected by, or suspected of being exposed to Toxoplasma. This may include cells from a subject and cells grown in culture. In some embodiments, a cell may be a control cell, which has not been exposed to toxoplasma. Cell types may include, but are not limited to, neuronal cells, ocular cells, erythrocytes, and intestinal cells.
- toxoplasma infection and “toxoplasmosis” refer to infection by all members of the genus Toxoplasma.
- the application of the invention is described in many cases with reference to Toxoplasma gondii parasites, and is intended to include application of the methods to all strains Toxoplasma gondii.
- the methods of the invention are also envisioned to apply to treatment of toxoplasma parasite infections that result from other toxoplasma species.
- Particularly important subjects to which the present invention can be applied are subjects having been or suspected of having been exposed to toxoplasma, which includes subjects diagnosed with infection, exhibiting symptoms of infection, or having known or probable risk of exposure to toxoplasma infection.
- a subject may or may not exhibit symptoms of infection such as fever, swollen lymph glands, muscle aches, and pains.
- Methods to diagnose symptomatic and asymptomatic toxoplasma infection are known to those of ordinary skill in the medical arts and include, but are not limited to, blood tests for antibodies to the toxoplasma parasite.
- Brain scans by computerized tomography (CT scan) or magnetic resonance imaging (MRI scan) may also be used in the diagnosis of toxoplasma infection.
- Treatment as it relates to the invention may be prophylactic or therapeutic.
- Prophylactic and therapeutic treatment may involve administering a vaccine to induce/augment an immunoprotective response, or a polypeptide such as an antibody that binds TgAMA-1, to interfere with the toxoplasma parasite in the subject.
- the antibody to TgAMA-1 is administered to inhibit infection in a subject.
- the term “reduce likelihood of infection” means to reduce or lower the level of entry into cells by the toxoplasma parasite.
- inhibit or block may also mean to prevent entry into the cells by toxoplasma, but it is not necessary to prevent all entry to lessen or prevent the manifestation of disease.
- TgAMA-1 polypeptides means the polypeptide set forth as SEQ ID NO: 1, variants of the polypeptide set forth as SEQ ID NO: 1, and fragments of the polypeptide set forth as SEQ ID NO: 1.
- the invention provides isolated TgAMA-1 polypeptides and TgAMA-1 binding polypeptides, such as antibodies, that bind to TgAMA-1 polypeptides.
- the invention also embraces functional variants, such as fragments, of the TgAMA-1 polypeptides.
- a “functional variant” or “variant” TgAMA-1 polypeptide is a molecule that contains one or more modifications to the primary amino acid sequence of the TgAMA-1 polypeptide and retains the antigenic function of TgAMA-1. Modifications that create a TgAMA-1 polypeptide functional variant can be made, for example, to enhance a property of an TgAMA-1 polypeptide, such as peptide stability in an expression system or the antigenicity of the TgAMA-1 protein; or to provide a novel activity or property to a TgAMA-1 polypeptide, for example, to enhance detection.
- Modifications to a TgAMA-1 polypeptide can be made to a nucleic acid that encodes the peptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, substitution of one amino acid for another and the like. Modifications also embrace fusion proteins comprising all or part of the TgAMA-1 polypeptide amino acid sequence.
- the amino acid sequence of polypeptides may be of natural or non-natural origin, that is, they may comprise a TgAMA-1 polypeptide molecule or may comprise a modified sequence as long as the amino acid sequence retains the antigenic property of TgAMA-1.
- TgAMa-1 polypeptides in this context may be fusion proteins of a TgAMA-1 polypeptide and unrelated amino acid sequences, synthetic peptides of amino acid sequences shown in SEQ ID NO: 1, peptides isolated from cultured cells that express TgAMA-1, and peptides coupled to nonpeptide molecules (for example in certain drug delivery systems, e.g., across a cell membrane, or detectable labels).
- mice An example, although not intended to be limiting, of a method with which antigenicity of a TgAMA-1 polypeptide can be tested involves in vivo testing in mice.
- One test involves the ability to enhance an antibody response to an antigen component of the TgAMA-1 antigen and/or the delayed-type hypersensitive (DTH) response, measured by an increase in footpad swelling after inoculation in the footpad of the test animal. These measurements can then be compared to corresponding measurements in control animals.
- Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation). Serum can be analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA.
- DTH response to the antigen may be measured after the final inoculation (e.g. within 1-7 days).
- the functional variant of the TgAMA-1 polypeptide may have conservative amino acid substitutions, i.e., substitutions which retain a property of the original amino acid such as charge, hydrophobicity, conformation, etc.
- conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.
- a motif might specify that the residue at a TgAMA-1 peptide position may be any one of the residues valine, leucine, isoleucine, methionine, or phenylalanine; that the residue at the second position must be histidine; that the residue at the third position may be any amino acid residue; that the residue at the fourth position may be any one of the residues valine, leucine, isoleucine, methionine, phenylalanine, tyrosine or tryptophan; and that the residue at the fifth position must be lysine.
- Sequence motifs for the TgAMA-1 polypeptide functional variants can be developed by analysis of the antigenic regions of the TgAMA-1 polypeptide disclosed herein. By providing a detailed structural analysis of the residues involved in the antigenicity of the TgAMA-1 polypeptide disclosed herein, one of ordinary skill in the art is enabled to make predictions of sequence motifs for antigenic regions of the TgAMA-1 polypeptides.
- the ability of the variant TgAMA-1 polypeptides to inhibit toxoplasma parasite entry into cells is determined according to standard procedures.
- the variant polypeptide can be contacted with the parasite, and standard procedures may be used to determine whether the parasite is inhibited in its ability to enter cells.
- Variant TgAMA-1 polypeptides include “fragments” of the polypeptide having SEQ ID NO:1. As used herein, a fragment has one or more amino acids fewer than the polypeptide set forth as SEQ ID NO:1. Those of ordinary skill in the art may apply no more than routine procedures to identify such fragments, in view of the disclosures provided herein.
- Variants and fragments as well as TgAMA-1 binding peptides such as antibodies may be tested for their ability to inhibit Toxoplasma activity.
- One method for inhibiting activity is by inhibiting entry of toxoplasma into cells.
- the ability to inhibit entry of toxoplasma parasite into cells with a TgAMA-1 polypeptide or binding polypeptide can be assessed using routine screening assays, e.g. by determining the level of TgAMA-1 mediated entry of Toxoplasma parasite into cells with and without the presence of the polypeptide.
- the ability of a putative TgAMA-1 polypeptide or binding polypeptide to out-compete toxoplasma parasite entry into cells can be determined by comparing the binding of the parasite TgAMA-1 to the cell in the presence and absence of the putative TgAMA-1 polypeptide or binding polypeptide. By comparing putative TgAMA-1 polypeptides or other binding peptides with the peptide of SEQ ID NO:1, additional polypeptides with increased parasite inhibiting properties can be identified.
- Nucleic acid sequences that code for a TgAMA-1 polypeptide or binding polypeptides, including allelic variants, are also a part of the invention.
- an “isolated TgAMA-1 nucleic acid molecule” is a nucleic acid molecule that encodes an antigenic TgAMA-1 polypeptide.
- a TgAMA-1 nucleic acid molecule can be the nucleic acid molecule set forth as SEQ ID NO:2 or can be a fragment thereof.
- the TgAMA-1 nucleic acid molecules of the invention can also be variants of the nucleotide sequence set forth as SEQ ID NO:2.
- the invention also encompasses Watson-Crick complements of the foregoing TgAMA-1 nucleic acid molecules.
- the TgAMA-1 nucleic acids of the invention may encode fragments or variants of the polypeptide set forth as SEQ ID NO:1.
- the TgAMA-1 nucleic acids of the invention do not encode the entire TgAMA-1 polypeptide of SEQ ID NO:1, but do include nucleotide sequences encoding the TgAMA-1 polypeptide fragments disclosed herein, or functional equivalents thereof.
- nucleic acid hybridization such as a Southern blot or a Northern blot may be performed under high stringency conditions, together with a labeled probe, for example, a 32 P probe.
- high stringency conditions refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, or Current Protocols in Molecular Biology, F. M.
- Exemplary high stringency conditions include hybridization at 65° C. in hybridization buffer (3.5 ⁇ SSC, 0.02% Ficoll, 0.02% Polyvinyl pyrolidone, 0.02% Bovine Serum Albumin, 25 mM NaH 2 PO 4 (pH7), 0.5% SDS, 2 mM EDTA).
- SSC is 0.15M Sodium Chloride/0.015M Sodium Citrate, pH 7;
- SDS is Sodium Dodecyl Sulphate; and
- EDTA is Ethylene diaminetetraacetic acid.
- the membrane upon which the DNA is transferred can be washed, for example, at 2 ⁇ SSC at room temperature and then at 0.1-0.5 ⁇ SSC/0.1 ⁇ SDS at temperatures up to 68° C. After washing the membrane to which DNA encoding a TgAMA-1 immunogenic polypeptide is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal.
- the invention also includes the use of nucleic acid sequences which include alternative codons that encode the same amino acid residues of the TgAMA-1 polypeptide or binding polypeptide of the invention.
- leucine residues can be encoded by the codons CUA, CUC, CUG, CUU, UUA and UUG.
- Each of the six codons is equivalent for the purposes of encoding a leucine residue.
- any of the leucine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, in vitro or in vivo, to incorporate a leucine residue.
- nucleotide sequence triplets which encode other amino acid residues comprising the TgAMA-1 polypeptide include: GUA, GUC, GUG and GUU (valine codons); GGU, GGA, GGG, GGC (glycine codons); UAC and UAU (tyrosine codons).
- Other amino acid residues may be encoded similarly by multiple nucleotide sequences.
- the invention embraces degenerate nucleic acids that differ from the native TgAMA-1 polypeptide encoding nucleic acids in codon sequence due to the degeneracy of the genetic code.
- the invention also provides modified nucleic acid molecules, which include additions, substitutions and deletions of one or more nucleotides.
- these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as antigenicity, etc.
- the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein.
- the modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.
- modified nucleic acid molecules that encode polypeptides having single amino acid changes can be prepared.
- Each of these nucleic acid molecules can have one, two, or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein.
- modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes.
- Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on.
- each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions.
- Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.
- a host cell is any cell capable of expressing a peptide in the presence of appropriate expression vectors.
- Host cells include but are not limited to prokaryotic (e.g., E. coli ), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells, plasmids in High FiveTM Cells).
- prokaryotic e.g., E. coli
- eukaryotic e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells, plasmids in High FiveTM Cells
- Especially useful are insect cells as host cells for expression in the invention.
- An example of useful insect cells although not intended to be limiting, are High FiveTM insect cells (see Examples).
- Plants may also be used to express the TgAMA-1 vaccines of the invention.
- the expression vectors require that the pertinent sequence, i.e., those described supra, be operably linked to a promoter.
- the polypeptides of the invention may be produced in host cells and delivered to a subject.
- the peptides may be produced in vivo following administration of an expression vector with the TgAMA-1 nucleic acid to a subject. Delivery of expression vectors encoding the TgAMA-1 sequences in vivo and/or in vitro can be via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., Eur. J Immunol. 26(8):1951-1959, 1996).
- Recombinant vectors including viruses selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses such as NYVAC, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle, plasmids (e.g. “naked” DNA), bacteria (e.g. the bacterium Bacille Calmette Guerin, BCG), and the like can be used in such delivery.
- the expression vectors can be administered in vivo to produce the antigen as a vaccine.
- viruses, expression vectors and the like which are useful in preparation of a vaccine antigen in vivo are known to one of ordinary skill in the art. Since nucleic acids have some adjuvant properties an antigen expressed in vivo from an expression vector may not require an additional adjuvant.
- TgAMA-1 molecule delivery systems in standard model systems such as mice to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.
- a “vector” may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell.
- Vectors are typically composed of DNA although RNA vectors are also available.
- Vectors include, but are not limited to, plasmids, phagemids, bacteria and virus genomes as disclosed herein, such as adenovirus, poxvirus and BCG.
- a cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell.
- replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis.
- replication may occur actively during a lytic phase or passively during a lysogenic phase.
- An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript.
- Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector.
- Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., ⁇ -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein).
- Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.
- a coding sequence and regulatory sequences are said to be “operably” joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5′ regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein.
- a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.
- some nucleic acids express only fragments of TgAMA-1 polypeptides that include antigenic fragments.
- regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5′ non-transcribed and 5′ non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like.
- 5′ non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene.
- Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired.
- the vectors of the invention may optionally include 5′ leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.
- RNA heterologous DNA
- TgAMA-1 TgAMA-1 polypeptide of the invention
- Preferred systems for mRNA expression in mammalian cells are those such as pcDNA3.1 (available from Invitrogen, Carlsbad, Calif.) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences.
- pcDNA3.1 available from Invitrogen, Carlsbad, Calif.
- CMV human cytomegalovirus
- suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element.
- EBV Epstein Barr virus
- Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 ⁇ , which stimulates efficiently transcription in vitro.
- the plasmid is described by Mishizuma and Nagata ( Nuc. Acids Res. 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin ( Mol. Cell. Biol. 16:4710-4716, 1996).
- Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins ( J. Clin. Invest. 90:626-630, 1992). The use of the adenovirus to express proteins for immunization is disclosed by Wamier et al., in intradermal injection in mice for immunization against P1A ( Int. J Cancer, 67:303-310, 1996).
- the invention also embraces expression kits, which allow the artisan to prepare a desired expression vector or vectors.
- expression kits include at least separate portions of at least two of the previously discussed materials. Other components may be added, as desired.
- transgenic non-human animals comprising the expression vector of the invention.
- Such transgenic animals are capable of expressing a variable level of TgAMA-1 polypeptide.
- a mammal is genetically modified to produce TgAMA-1 in its milk Techniques for performing such genetic modifications are described in U.S. Pat. No. 6,013,857, issued Jan. 11, 2000 for :Transgenic Bovines and Milk from Transgenic Bovines.”
- the genome of the transgenic animal is modified to comprise a transgene comprising a DNA sequence encoding TgAMA-1 operably linked to a mammary gland promoter. Expression of the DNA sequence results in the production of TgAMA-1 in the milk.
- TgAMA-1 may then be isolated from milk obtained from the transgenic mammal (e.g. using a column comprising an antibody which binds to TgAMA-1).
- the transgenic mammal is preferably a bovine species.
- TgAMA-1 binding polypeptides include but are not limited to anti-TgAMA-1 antibodies including polyclonal and monoclonal antibodies, antibody fragments, and other non-antibody peptides.
- Antibodies useful in the methods of the invention include but are not limited to monoclonal antibody B3.90, which binds to TgAMA-1 and is described herein, and polyclonal antibodies such as UVT59, which is described herein.
- TgAMA-1 binding polypeptides e.g. anti-TgAMA-1 antibodies
- TgAMA-1 binding polypeptides selectively bind to TgAMA-1 polypeptides and in some embodiments inhibit entry of Toxoplasma gondii or other toxoplasma parasite into cells.
- TgAMA-1 binding polypeptides are prepared by standard methods.
- the invention also permits the artisan to treat a subject having a toxoplasma infection or at risk of developing a toxoplasma infection.
- Treatments include administering TgAMA-1 polypeptides, optionally in the form of a vaccine or a TgAMA-1 binding polypeptide, including the anti-TgAMA-1 antibodies of the invention disclosed herein.
- the TgAMA-1 polypeptides and anti-TgAMA-1 antibodies of the invention are used to produce antibodies (“anti-TgAMA-1 antibodies”) using standard techniques well known to the art. Standard reference works setting forth the general principles of antibody production include Catty, D., Antibodies, A Practical Approach, Vol. 1, IRL Press, Washington D.C.
- the antibodies of the present invention are prepared using any of a variety of methods, including administering the TgAMA-1 polypeptides of the invention, antibodies selective for the foregoing, and the like to an animal to induce monoclonal or polyclonal antibodies.
- the production of monoclonal antibodies is according to techniques well known in the art.
- Non-limiting examples of supports for affinity-separation of antibodies, including monoclonals include the following: activated Sepharose, activated cellulose and activated Sephadex. “Activated” refers to the creation, on the insoluble material, of reactive chemical groups that will form covalent linkages with the antibody molecules when incubated together under appropriate conditions. Typically, reactive groups are introduced into the insoluble substrate by the action of cyanogen bromide (CNBr) at high pH.
- CNBr cyanogen bromide
- an antibody from which the pFc′ region has been enzymatically cleaved, or which has been produced without the pFc′ region designated an F(ab′) 2 fragment, retains both of the antigen binding sites of an intact antibody.
- an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule.
- Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.
- CDRs complementary determining regions
- FRs framework regions
- CDR1 through CDR3 complementarity determining regions
- PCT International Publication Number WO92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin.
- Such antibodies including fragments of intact antibodies with antigen-binding ability, are often referred to as “chimeric” antibodies.
- the present invention also provides for F(ab′) 2 , Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab′) 2 fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and
- chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences.
- the present invention also includes so-called single chain antibodies and human monoclonal antibodies, such as those produced by mice having functional TgAMA-1 loci.
- Antibodies also may be used to identify tissues expressing protein or to purify protein. Antibodies, also may be coupled to specific labeling agents for imaging or to anti-infectious agents, toxins such as ricin, other cytostatic or cytolytic drugs, and so forth, for therapeutic purposes.
- the invention also involves the use of anti-idiotypic antibodies.
- anti-idiotypic antibodies By using monoclonal antibodies that interact with TgAMA-1 polypeptide, it is also possible to produce anti-idiotypic antibodies which can be used to screen other molecules to identify whether the other molecule has the same binding specificity as the monoclonal antibody.
- anti-idiotypic antibodies can be produced using well-known hybridoma techniques (Kohler and Milstein, Nature, 256:495, 1975).
- An anti-idiotypic antibody is an antibody which recognizes unique determinants present on the known monoclonal antibodies. These determinants are located in the hypervariable region of the antibody. It is this region which binds to a given epitope and, thus, is responsible for the specificity of the antibody.
- An anti-idiotypic antibody can be prepared by immunizing an animal with a monoclonal antibody.
- the immunized animal will recognize and respond to the idiotypic determinants of the immunizing monoclonal antibodies and produce an antibody to these idiotypic determinants.
- the anti-idiotypic antibodies of the immunized animal which are specific for the monoclonal antibodies of the invention, it is possible to identify other clones with the same idiotype as the monoclonal antibody used for immunization.
- Idiotypic identity between monoclonal antibodies of two cell lines demonstrates that the two monoclonal antibodies are the same with respect to their recognition of the same epitopic determinant.
- anti-idiotypic antibodies it is possible to identify other hybridomas expressing monoclonal antibodies having the same epitopic specificity.
- an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the image of the epitope bound by the first monoclonal antibody.
- compositions of the present invention are administered in pharmaceutically acceptable preparations.
- Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.
- pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients.
- the characteristics of the carrier will depend on the route of administration.
- the therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time.
- the administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intranasal, intracavity, subcutaneous, intradermal, or transdermal.
- Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
- a “vaccine’ as used herein is an antigen in a pharmaceutical formulation and optionally includes an adjuvant.
- immuno or “vaccination” means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen.
- Generally accepted animal models can be used for testing of immunization against toxoplasma using a toxoplasma antigen polypeptide or nucleic acid.
- toxoplasma parasite can be introduced into a mouse to create the disease, and one or more toxoplasma antigen can be delivered by the methods described herein.
- the effect on the toxoplasma disorder can be assessed as a measure of the effectiveness of the toxoplasma antigen immunization.
- testing of the foregoing animal model using more conventional methods for immunization include the administration of one or more toxoplasma antigen polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response.
- Methods for immunization including formulation of a vaccine composition and selection of doses, route of administration and the schedule of administration (e.g.
- test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing the antigen and so forth.
- one or more TgAMA-1 polypeptides are administered optionally with one or more adjuvants to induce an immune response or to increase an immune response.
- An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response.
- Adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-analyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-analanine-2-(1′-2′dipalmitoyl-sn-glycero-3-hydroxyphosphroyloxy)-ethylamine, monophosphoryl lipid A; saponins (QS21; DQS21); QS-7, QS-17, QS-18, and QS-L1; incomplete Freund's adjuvant; complete Freund's adju
- Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes.
- Adjuvants of many kinds are well known in the art.
- the polypeptides are administered mixed with a combination of DQS21I/MPL.
- the ratio of DQS21 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1.
- DQS21 and MPL will be present in a vaccine formulation in the range of about 1 ⁇ g to about 100 ⁇ g.
- Other adjuvants are known in the art and can be used in the invention (see, e.g. Goding, Monoclonal Antibodies: Principles and Practice, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.
- cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties.
- cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-1 2) which has been shown to enhance the protective effects of vaccines (see, e.g., Science 268: 1432-1434, 1995), GM-CSF and IL-18.
- IL-1 2 interleukin-12
- GM-CSF GM-CSF
- IL-18 interleukin-18
- the vaccine is a proteosome vaccine.
- Proteosomes are useful for immunopotentiation by rendering peptides immunogenic and enhancing the immunostimulating properties of larger peptides, proteins, and protein fragments.
- Methods for preparing proteosomes include, but are not limited to, preparation from meningococci, as described in U.S. Pat. No. 5,726,292, the contents of which is hereby incorporated in its entirety.
- the preparations of the invention are administered in effective amounts.
- An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, stimulates the desired response.
- the desired response is inhibiting the onset, stage or progression of the disease or infection. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently, or preventing infection.
- the TgAMA-1 molecule dosage may be adjusted by the individual physician or veterinarian, particularly in the event of any complication.
- a therapeutically effective amount typically varies from 0.01 mg/kg to about 1000 mg/kg, preferably from about 0.1 mg/kg to about 200 mg/kg, and most preferably from about 0.2 mg/kg to about 20 mg/kg, in one or more dose administrations daily, for one or more days.
- the absolute amount will depend upon a variety of factors, including the material selected for administration, whether the administration is in single or multiple doses, and individual patient parameters including age, physical condition, size, weight, and the stage of the disease. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
- the therapeutically effective amount of the TgAMA-1 molecule is that amount effective to inhibit toxoplasma entry into cells. Such inhibition can be determined using standard assays as described above. In other embodiments a therapeutically effective amount is that amount effective to induce an immune response against the parasite. Measurements of acute toxoplasma infection, including isolation of the parasite from either blood or other body fluids after subinoculation of the body fluid into the peritoneal cavity of mice can be used to assess the levels of parasites remaining in the blood after exposure. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998).
- Toxoplasma gondii in a subject's body fluid represents an acute infection, and the presence of Toxoplasma gondii in tissue biopsies is an indication only of the presence of tissue cysts and not acute toxoplasmosis. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998). Additional methods of diagnosis and assessment of chronic and acute toxoplasma infection are known to those of skill in the art.
- the methods currently available for this determination are the double-sandwich IgM-ELISA and the IgM-immunosorbent assay (IgM-ISAGA).
- the double-sandwich IgA-ELISA is more sensitive than the IgM-ELISA for detecting congenital infection in the fetus and newborn. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998).
- toxoplasma infection can be monitored for assessment of infection.
- features include, but are not limited to: assessment of the presence of eye lesions, brain lesions, and brain inflammation.
- assessment can be with methods known to one of ordinary skill in the art, such as ophthalmologic testing, CSF evaluation, and radiologic studies. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998).
- toxoplasma infection status of a subject may be assessed using various types of tests, as well as others known to those of ordinary skill in the medical arts.
- a first determination of toxoplasma infection may be obtained using one of the methods described above, and a subsequent determination of infection can be done and a comparison of the infection levels may be used to assess the effectiveness of TgAMA-1 molecule or TgAMA-1 binding polypeptides administration as a prophylactic or a treatment of the toxoplasma infection.
- Absence of a toxoplasma infection may be an indication for prophylactic intervention by administering TgAMA-1 molecules or TgAMA-1 binding polypeptides to prevent toxoplasma infection.
- TgAMA-1 molecules and TgAMA-1 binding polypeptides may be administered alone, in combination with each other, and/or in combination with other anti- toxoplasma drug therapies.
- Antitoxoplasma agents for treatment and/or prophylaxis
- TgAMA-1 molecules or TgAMA-1 binding polypeptides may include, but are not limited to: pyrimethamine plus either sulfadiazine or clindamycin; trimethoprim; protein synthesis inhibitors such as clindamycin, chlortetracycline, and azithromycin;.
- purine synthesis inhibitors such as arprinocid; atovaquone; spiramycin plus prednisone; Dapsone (diaminodiphenyl sulfone); macrolides including roxithromycin, clarithromycin, and azithromycin; and phenytoin.
- the above-described drug therapies are well known to those of ordinary skill in the art and are administered by modes known to those of skill in the art.
- the drug therapies are administered in amounts that are effective to achieve the physiological goals (to reduce toxoplasma infection, and/or reduce toxoplasma titer in a subject), in combination with the TgAMA-1 molecules of the invention.
- the drug therapies may be administered in amounts which are not capable of preventing or reducing the physiological consequences of the toxoplasma infections when the drug therapies are administered alone, but which are capable of preventing or reducing the physiological consequences of toxoplasma infection when administered in combination with the TgAMA-1 molecules of the invention.
- the vaccine formulations of the invention may be administered to confer immunity to a subject at risk of exposure to toxoplasma, which thereby prevents, reduces the severity of or delays the onset of a subsequent Toxoplasma infection.
- the vaccines may be administered during an ongoing Toxoplasma infection to improve the effectiveness of the host's response to the infections Toxoplasma organism.
- the invention also provides a pharmaceutical kit comprising one or more containers comprising one or more of the TgAMA-1 molecules and/or antibodies of the invention and or formulations of the invention.
- the kit may also include instructions for the use of the one or more TgAMA-1 molecules and/or antibodies of the invention for the treatment of toxoplasma infection.
- T. gondii tachyzoites (RH strain, unless otherwise indicated) were cultured in human foreskin fibroblasts as previously described [5] and filtered through a 10 ⁇ m polycarbonate filter (Poretics, Livermore Calif.) prior to use.
- MAbs MAb B3.90 (against TgAMA-1) and A3.2 (against GRA8) were generated as described [3, 6] and purified by ion exchange and gel filtration chromatography [7]. Ascites fluid containing MAb 6D10 (against MIC2) was prepared as described [1]. Ascites fluid containing MAb Tg49 (against ROP1) was generously provided by Joseph Schwartzman (Dartmouth College, Hanover N.H.). MAb 40-1a (against E. coli ⁇ -galactosidase) was developed by J. R. Sanes and obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Department of Biological Sciences, Iowa City Iowa) as a hybridoma supernatant.
- Polyclonal antibody UVT59 A synthetic peptide corresponding to residues 496-515 of TgAMA-1 (acetyl-EFQSDRGARKKRPSDLMQEAC-amide (SEQ ID NO:3)) was coupled to keyhole limpet hemocyanin using the Imject Maleimide Activated mcKLH Kit (Pierce, Rockford Ill.). The peptide-carrier conjugate was used to generate rabbit polyclonal antisera (Cocalico Biologicals Inc., Reamstown Pa.); serum titers were determined by western blot and immunofluorescence microscopy.
- Synthetic peptide coupled to agarose using the SulfoLink Kit was used to affinity purify AMA-I-specific antibody UVT59 from total serum as recommended by the manufacturer, except that 0.01 vol of stock protease inhibitors (aqueous stock contains 2 mg/ml aprotinin, 2 mg/ml leupeptin, 16 mg/ml benzamidine, and 5 mg/ml 4-(2-aminoethyl)-phenylsulfonylfluoride; DMSO stock contains 5 mg/ml pepstatin) were added to the serum before applying it to the peptide column.
- aqueous stock contains 2 mg/ml aprotinin, 2 mg/ml leupeptin, 16 mg/ml benzamidine, and 5 mg/ml 4-(2-aminoethyl)-phenylsulfonylfluoride; DMSO stock contains 5 mg/ml pepstatin
- Proteins were resolved by SDS-PAGE in the presence (reducing) or absence (non-reducing) of 5% (v/v) ⁇ -mercaptoethanol and western blotted as described[3], using MAb B3.90, MAb 6D10, MAb 40-1a and polyclonal serum UVT 59 at dilutions of 23.2 ⁇ g/ml, 1/5000 (v/v), 1/100 (v/v), and 1/10,000 (v/v), respectively. Where indicated, blots were stripped by sequential incubation in PBS (2 changes, 5 min each), 4% (w/v) trichloroacetic acid (2 changes, 10 min each), and PBS (2 changes, 5 min each). Stripped blots were either reblocked and probed with a different antibody or exposed directly to X-ray film.
- Triton X-114 (TX-114) Phase Partitioning
- TX-114 phase partitioning of total parasite extracts was carried out as previously described [6]. After partitioning, the detergent phase was diluted to the original extract volume (4 ⁇ 10 7 parasite equivalents/ml) with 50 mM Tris-HCl, pH 7.4 and 100 mM NaCl, supplemented with 3.0 U/ml Bacillus cereus phosphatidylinositol-specific phospholipase C (PI-PLC; Molecular Probes, Eugene Oreg.) and sequentially incubated for 5 min on ice, 35 min at 37° C. and 5 min on ice. The PI-PLC-treated detergent phase was then subjected to 2 additional rounds of phase partitioning, and analyzed by SDS-PAGE/western blotting.
- PI-PLC Bacillus cereus phosphatidylinositol-specific phospholipase C
- MAb B3.90 was covalently cross-linked to Affi-Gel Protein A-conjugated agarose (BioRad, Hercules Calif.) as previously described [8]. Approximately 2.5 mg of IgG was coupled per 1 ml of resin. Parasites were washed twice in phosphate-buffered saline (PBS), pH 7.4 and extracted for 45 min on ice in EXTR buffer (0.5% [v/v] Triton X-100 (TX-100), 50 mM Tris, pH 7.4, 100 mM NaCl) supplemented with 0.01 volumes of the aqueous and DMSO protease inhibitor stocks. The extracts were centrifuged at 14,000 ⁇ g for 5 min at 4° C.
- PBS phosphate-buffered saline
- EXTR buffer 0.5% [v/v] Triton X-100 (TX-100), 50 mM Tris, pH 7.4, 100 mM NaCl
- the pooled eluate was concentrated 10-fold using a Centricon RC/YM-30 centrifugal filter device (30,000 MWCO; Millipore, Bedford Mass.) and subjected to SDS-PAGE.
- the gel was stained for 30 min with 0.1% (w/v) Coomassie R-250 in 50% (v/v) methanol, 10% (v/v) acetic acid and destained for 1 h in 10% (v/v) methanol and 7.5% (v/v) acetic acid.
- the purified antigen was cut out of the gel, digested with trypsin, and analyzed at the Harvard Microchemistry Facility (Cambridge Mass.) by microcapillary reverse-phase HPLC nano-electrospray tandem mass spectrometry ( ⁇ LC/MS/MS) on a Finnigan LCQ quadropole ion trap mass spectrometer.
- the fragmentation spectra were correlated with known sequences using previously described algorithms [9, 10].
- PBS-BSA bovine serum albumin
- Unfixed/unpermeabilized suspension assay Tachyzoites were washed twice in PBS, pH 7.4 by centrifugation for 4 min at 1000 ⁇ g (23° C) and incubated for 10 min at 4° C. in PBS-BSA, followed by 1 hr at 4° C. in PBS-BSA containing primary antibody, diluted as above.
- the labeled cells were washed 3 times in PBS, post-fixed 25 min at 4° C. in PBS containing 2.5% (v/v) formaldehyde and 0.025% (v/v) glutaraldehyde, washed 3 times in PBS, incubated with fluorescently conjugated secondary antibody as above, washed 5 times in PBS and mounted on glass slides in PBS for observation.
- Digitized images were obtained using either a VE1000SIT camera (Dage-MTI, Michigan City Ind.) with an LG-3 framegrabber and Scion Image v 1.6 software (Scion Corp., Frederick Md.) or a SpotRT monochrome camera driven by Spot v.3.01 (AppleEvent) software (Diagnostic Instruments Inc., Sterling Heights Mich.).
- Tachyzoites (2F strain, constitutively expressing cytoplasmic ⁇ -galactosidase [generous gift of David Sibley]) were washed twice in DMEM+20 mM HEPES, pH 7.0 (4 min, 1000 ⁇ g, 23° C.), and resuspended in 4 ml polystyrene round bottom tubes at a concentration of 2 ⁇ 10 8 tachyzoites/ml. The suspension was incubated for various times at 37° C. or treated for 15 min at 23° C. with either 1.0% (v/v) DMSO or 20 ⁇ M BAPTA-AM (1.0% [v/v] DMSO final), followed by 2 min at 37° C.
- a subcellular fraction enriched in micronemes was prepared as described [2] except that the microneme fraction was extracted with 0.01% saponin to recover the micronemal contents.
- INA was synthesized from 5-aminonaphthalene-1-azide [11] and labeled with 125 I (Lofstrand Laboratories, Gaithersburg, Md.) to a specific activity of ⁇ 1 mCi/ ⁇ mol.
- Filtered parasites from a freshly lysed monolayer of human foreskin fibroblasts were washed twice (1000 ⁇ g, 4 min, 23° C.) with IM-PR (phenol-red deficient DMEM+20 mM HEPES, pH 7.0), and resuspended in IM-PR to a concentration of 2 ⁇ 10 8 tachyzoites/ml.
- Reduced glutathione was added to a concentration of 15 mM.
- UVP Inc. San Gabriel Calif.; Model UV6-54, 254 nm
- the parasites were pelleted (14,000 ⁇ g, 5 min) and extracted (1.4 ⁇ 10 6 tachyzoites/ ⁇ l, 45 min, 4° C.) in 0.5% (v/v) TX-100, 50 mM Tris pH7.4, 100 mM NaCl, 2 mM EDTA supplemented with 0.01 volumes of the aqueous and DMSO protease inhibitor stocks.
- Affinity purified polyclonal antibody UVT59 was coupled to agarose beads and 36 ⁇ l of beads were used to immunoprecipitate TgAMA-1 from 75 ⁇ l of the TX-100 extract as described above. Immunoprecipitated proteins eluted from the beads in 36 ⁇ l of sample buffer were analyzed by SDS-PAGE under reducing conditions and western blotted with antipeptide antiserum as described above. The membrane was then stripped as described above and exposed to BioMax MS X-ray film (Eastman Kodak, Rochester N.Y.) at ⁇ 70° C.
- MAb B3.90 In experiments designed to identify novel, non-GPI-linked apical or peripheral tachyzoite antigens [3, 6], a MAb (B3.90) was generated that reacts with a 63 kDa protein on western blots of total tachyzoite extracts, and shows both apical and peripheral localization by immunofluorescence (see below). MAb B3.90 recognizes a 63 kDa antigen on western blots of non-reduced tachyzoite extracts. No bands were detected when the samples were treated with ⁇ -mercaptoethanol prior to SDS-PAGE.
- TX-114 phase partitioning experiments the 63 kDa antigen is recovered in the detergent phase both before and after treatment with PI-PLC, consistent with the behavior of a non-GPI-linked, transmembrane protein.
- TX-114 phase partitioning tachyzoites (Total) were extracted on ice in a buffer containing 0.5% (v/v) TX-114 and the cleared extract (TX-114 Soluble) was separated into aqueous (Aqueous I) and detergent (Detergent I) phases at 37° C. The detergent phase was incubated with PI-PLC and partitioned again into aqueous (AqueousII) and detergent (DetergentII) phases.
- the 63 kDa antigen was purified by immunoaffinity chromatography using MAb B3.90. Tryptic peptides prepared from the purified protein were analyzed by tandem microcapillary reverse-phase HPLC/ion trap mass spectrometry. The resultant fragmentation spectra unambiguously identified the 63 kDa antigen as Genbank entry AF010264 (deposited by Hehl, Oretga-Barria and Boothroyd), the Toxoplasma homolog (TgAMA-1) of Plasmodium AMA-1. Multiple sequence alignment of TgAMA-1 with AMA-1 from the different Plasmodium species revealed significant homology across all species.
- TgAMA-1 a putative signal peptide, with a predicted cleavage site between residues 22 and 23 (ASG-LS), and a potential transmembrane domain between residues 457 and 476.
- TgAMA-1 is a Microneme Protein
- TgAMA-1 To localize TgAMA-1 in T. gondii, we performed dual label immunofluorescence microscopy on free tachyzoites using MAb B3.90 and antibodies against known microneme (MIC2), rhoptry (ROP1), or dense granule (GRA8) antigens.
- MIC2 microneme
- ROP1 rhoptry
- GAA8 dense granule
- TgAMA-1 was found in a cap-like distribution at the apical end of the tachyzoite. This distribution is indistinguishable from that of MIC2, but distinctly different from that of GRA8 or ROP1, suggesting that TgAMA-1 resides in the micronemes of T. gondii tachyzoites.
- Immunoelectron microscopy with MAb B3.90 supports this conclusion, as does the enrichment of TgAMA-1 in a partially purified microneme fraction.
- TgAMA-1 tachyzoites were incubated at 37° C. in culture medium for various times, the cells were centrifuged, and assayed by western blot to determine the amount of TgAMA-1 released into the supernatant vs. the amount retained in the cell pellet. A 53-k′)a fragment of TgAMA-1 was found to be constitutively secreted into the supernatant in a time-dependent manner.
- TgAMA-1 or MIC2 The amount of TgAMA-1 or MIC2 released from live parasites into the culture supernatant after 0 m, 10 m, 30 m, 60 m, or 120 m at 37° C. was determined by western blotting is5 with either NMb B3.90 (TgAMA-1) or 6D10 (MIC2).
- TgAMA-1 NMb B3.90
- MIC2 6D10
- the estimated molecular masses of the secreted and cellular forms of TgAMA-1 were 53 and 63 kDa, respectively.
- the estimated molecular masses of full-length and processed forms of MIC2 are 115 kDa and 95-100 kDa, respectively [14].
- TgAMA-1 MAb B3.90
- MIC2 MAb 6D10
- B-A23187 A23187, following BAPTA-AM pretreatment
- B-ETOH ethanol, following BAPTA-AM pretreatment
- A23187 A23187, no BAPTA-AM pretreatment
- ETOH ethanol, no BAPTA-AM pretreatment
- TgAMA-1 appears to be constitutively processed and secreted from the parasite at 37° C.
- the secretion of the previously identified MIC proteins is enhanced by treatments which elevate intracellular calcium, including incubation with ethanol or the calcium ionophore A23187 [4, 15].
- the secretion of the 53-kDa fragment of TgAMA-1 was also found to be dramatically enhanced following a 2-min treatment with ethanol or ionophore A23187 this enhanced secretion was abrogated by pretreating the parasites with the membrane permeant calcium chelator, BAPTA-AM.
- TgAMA-1 While full-length TgAMA-1 requires detergent for its solubilization, the 53-kDa secreted form of the protein was recovered in the low speed supernatant in the secretion assays, in the absence of added detergent.
- the secreted fragment represents 53-kDa of the protein N-terminal to the putative transmembrane domain and that MAb B3.90 reacts with an epitope within this portion of TgAMA-1
- the anti-peptide antibody was found to be highly specific, recognizing a major 63 kDa band on western blots of tachyzoite extracts run under non-reducing condition (67 kDa under reducing conditions) and a minor band of approximately 12 kDa.
- the anti-peptide antiserum UVT59 recognized a major antigen of 63 kDa, and a minor antigen of 12 kDa on western blots of non-reduced tachyzoite extracts.
- the 63 kDa UVT59-reactive band migrated at 67 kDa under reducing conditions.
- the 12 kDa band was not detected on identical blots probed with MAb B3.90.
- Proteins of 67 and 12 kDa were also immunoprecipitated with the anti-peptide antibody, and are labeled in intact parasites with the photoactivatable hydrophobic probe 125 I-INA. Labeling of a protein with 125 I-INA provides evidence that a portion of the protein is embedded within a lipid bilayer [11].
- TgAMA-1 is proteolytically processed into at least two fragments: a 53 kDa N-terminal fragment which is released from the parasite and contains the epitope for MAb B3.90, and a 12 kDa C-terminal fragment which is recognized by the anti-peptide antibody and which remains associated with the parasite, presumably via its transmembrane domain.
- Secretion assay results are consistent with this model: the anti-peptide antibody recognizes full length TgAMA-1 and the 12 kDa peptide in the cell pellet but detects nothing in the supernatant after either 60 minutes of constitutive secretion or 2 minutes of ethanol/A23187-induced secretion.
- TgAMA-1 No soluble fragments of TgAMA-1 were detected with antipeptide antibody UVT59 in secretion assays. Parasites were preincubated for 2 min with or without BAPTA-AM, followed by a 2 min incubation in the presence of 1% ethanol. TgAMA-1 released into the assay supernatant was detected by western blotting with MAb B3.90; the blot was then stripped and reprobed with anti-peptide antibody UVT59. Significant ethanol-induced secretion of the 53 kDa peptide was observed with MAb B3.90; neither this fragment nor any other was detected in the supernatant using antipeptide antibody UVT59.
- TgAMA-1 and various fragments of TgAMA-1 have been expressed in E. coli, but Western blotting with the conformation-sensitive MAb B3.90 suggested that these recombinant fragments were incorrectly folded. Proper folding of recombinant protein is more likely to be obtained in eukaryotic cell expression systems. To this end, we have recently expressed recombinant TgAMA-1 in insect cells.
- Toxoplasma AMA-1 coding sequence corresponding to the signal peptide, ectodomain, and the transmembrane domain (amino acid residues 1-473) was amplified from cDNA and ligated into pIZ/V5-His(Invitrogen) in frame with both V5 and His eptiope tags.
- PIZ/V5-His encodes a ZeocinTM resistance selectable marker gene and the promoter, OpIE2, which drives constitutive expression of the inserted gene.
- the construct was transformed into E. coli and plasmid DNA was isolated from antibiotic resistant colonies.
- the presence of AMA-1 in pIZ/V5-His was confirmed by PCR, restriction digest analysis and sequencing.
- High FiveTM cells were transfected with pIZ/AMA-1/V5-His and stable expression was indicated by ZeocinTM resistance.
- Antibiotic-resistant insect cell lines were cloned either by limiting dilution or by aspirating foci; AMA-1 expression was assayed by indirect immunofluorescence microscopy using monoclonal antibody B3.90 and an Alexa 488-conjugated secondary antibody. Recombinant TgAMA-1 expression in insect cells was detected with mAb B3.90.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.
Description
- This application claims priority under 35 U.S.C. §119 to U.S. 60/247,870, filed Nov. 9, 2000, the entire contents of which is hereby incorporated by reference.
- This invention was made in part with government support under grant number R29A142355 from the National Institutes of Health (NIH). The government may have certain rights in this invention.
- The present invention relates to TgAMA-1, and TgAMA-1-based animal and human vaccines for toxoplasmosis.
- Toxoplasmosis is among the most common parasitic diseases of man. Serosurveys suggest prevalence rates as high as 70-90% in many areas of both the developing and developed world. Between 10-45% of Americans become infected at some point in their lives. An infection in an individual with a competent immune system generally has minor or no symptoms. The infection tends to be self-limiting, with the individual's immune system controlling and eliminating most of the parasites. Some parasites remain in bradyzoite form following acute infection and will be present in cysts in the central nervous system and muscle throughout the remainder of the individual's life.
- In contrast to the mild clinical symptoms of infection seen in a healthy individual with an intact immune system, subjects with weakened or otherwise compromised immune systems can have serious clinical effects from toxoplasma infection. In the fetus, toxoplasma infection can cause mental retardation, visual defects, and death. Toxoplasma infection can cause neurological damage, ocular lesions and death in adults with compromised immune systems, a group which includes for example individuals with HIV infection or patients undergoing immune-suppressive treatment for cancer.
- Acute toxoplasmosis can be difficult to treat. Sulfadiazine/pyramethamine is a regimen of choice, although side effects serious enough to warrant discontinuation of treatment are common. The toxic and potentially teratogenic effects of this regimen make management of the pregnant woman particularly problematic. AIDS patients require lifelong suppressive therapy to prevent relapse, and a many as one third of the patients receiving suppressive sulfadiazine/pyrimethamine therapy cannot tolerate the adverse side effects. For those who can tolerate the drugs, relapse occurs frequently. Pyrimethamine/clindamycin is a useful alternative therapy in AIDS patients who suffer an unusually high frequency of side effects from sulfa drugs. Unfortunately, this alternative combination can also cause considerable toxicity and is less effective at preventing relapse. Prevention of transmission through vaccination would be preferable to treatment, particularly for pregnant women and the immunocompromised.
- According to one aspect of the invention, isolated TgAMA-1 polypeptide molecules are provided. The TgAMA-1 polypeptide molecules include antigenic fragments of the polypeptide sequence set forth as amino acids SEQ ID NO:1.
- According to another aspect of the invention, fusion proteins are provided that include the foregoing antigenic polypeptide.
- According to another aspect of the invention, isolated TgAMA-1 nucleic acid molecules are provided. The TgAMA-1 nucleic acid molecules are selected from the group consisting of a fragment of the nucleotide sequence set forth as nucleotides 1-2507 of SEQ ID NO: 2 between 12 and 2506 nucleotides in length, and complements of (a), wherein the fragment encodes the foregoing isolated TgAMA-1 polypeptide.
- According to another aspect of the invention, expression vectors are provided and include the isolated foregoing TgAMA-1 nucleic acid molecule operably linked to a promoter.
- According to another aspect of the invention, expression vectors are provided and include an isolated nucleic acid molecule of SEQ ID NO: 2. operably linked to a promoter.
- According to another aspect of the invention, host cells transformed or transfected with the aforementioned expression vectors are provided. In some embodiments, the host cell is an insect cell. In certain embodiments, the insect cell is a High Five™ cell.
- According to another aspect of the invention, a transgenic non-human animal that includes the foregoing expression vector are provided. In some embodiments, the transgenic non-human animal expresses a variable level of TgAMA-1. In certain embodiments, the transgenic non-human animal expresses an antigenic fragment of SEQ ID NO: 1. In some embodiments, the transgenic non-human animal is a mammal. In certain embodiments, the transgenic non-human animal is a bovine.
- According to another aspect of the invention vaccine compositions are provided that include the foregoing isolated TgAMA-1 polypeptide and an adjuvant.
- According to yet another aspect of the invention, vaccine compositions are provided that include TgAMA-1 or a functionally active variant thereof, and an adjuvant.
- In some embodiments of the foregoing vaccine compositions the vaccine is a proteosome vaccine. In certain embodiments of the forgoing vaccine compositions, the adjuvant is selected from the group consisting of: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-analyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-analanine-2-( 1′-2′dipalmitoyl-sn-glycero-3-hydroxyphosphroyloxy)-ethylamine, monophosphoryl lipid A; saponins (QS21; DQS21); QS-7, QS-17, QS-18, and QS-L1; incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; vitamin E, oil emulsions, and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol.
- According to some aspects of the invention, methods for immunizing a subject are provided. The methods include administering to the subject an effective amount for immunizing the subject, of the foregoing vaccines. In some embodiments the subject is a mammal. In certain embodiments the subject is a human. In some embodiments, the subject is at risk of infection from Toxoplasma gondii. In some embodiments, the subject is a mammal. In certain embodiments, the subject is a human.
- According to another aspect of the invention, TgAMA-1 binding polypeptides that selectively bind to the foregoing isolated TgAMA-1 polypeptide are provided. In some embodiments, the TgAMA-1 binding polypeptide is an antibody or antigen-binding fragment of an antibody. In certain embodiments the antibody or antigen-binding fragment specifically binds to a region comprising about 12 or more cysteine residues of the forgoing isolated TgAMA-1 polypeptide. In certain embodiments, the binding polypeptide blocks entry of Toxoplasma parasite into a cell. In some embodiments, the TgAMA-1 binding polypeptide is a monoclonal antibody. In certain embodiments, the TgAMA-1 binding polypeptide is a humanized monoclonal antibody.
- According to another aspect of the invention, anti-idiotype antibodies that selectively bind to the TgAMA-1 binding polypeptides are provided.
- According to yet another aspect of the invention, methods for treating a toxoplasma infection are provided. The methods include administering to a subject in need of such treatment, an effective amount of the foregoing TgAMA-1 binding polypeptides to treat the toxoplasma infection. In some embodiments, the TgAMA-1 binding polypeptide blocks the entry of Toxoplasma parasite into a cell. In some embodiments, the subject is a mammal. In certain embodiments, the subject is a human.
- According to yet another aspect of the invention, methods for reducing the likelihood of a toxoplasma infection are provided. The methods include administering to a subject in need of such treatment, an effective amount of a foregoing TgAMA-1 binding polypeptide to reduce the likelihood of toxoplasma infection. In some embodiments, the TgAMA-1 binding polypeptide blocks the entry of Toxoplasma parasite into a cell. In some embodiments, the subject is a mammal. In certain embodiments, the subject is a human.
- The invention relates in some aspects to a Toxoplasma gondii tachyzoite protein termed TgAMA-1. TgAMA-1 is relatively homologous to the extensively studied apical membrane antigen-1 (AMA-1) family of proteins of malaria parasites. In animal models of malaria, passive immunization with polyclonal antibodies against AMA-1, or immmunization with native or recombinant renatured AMA-1, protect against parasite challenge; AMA-1 is currently under investigation as a vaccine candidate for human malaria. The antigenicity of malarial AMA-1 resides in its extracellular domain, with which TgAMA-1 shows a high degree of structural conservation. The present invention relates to the use of recombinant TgAMA-1 and its extracellular domain as vaccines for toxoplasmosis. The efficacy of TgAMA-1 as a vaccine is readily confirmed by administering TgAMA-1 and/or vaccine formulations comprising TgAMA-1 to test animals, such as mice. Cats and sheep (important animal reservoirs of Toxoplasmosis) are also readily tested to confirm the vaccine potential of TgAMA-1, as well as ultimately, humans.
- As used herein, the term “TgAMA-1” means human Toxoplasma gondii apical membrane antigen-1. As used herein the term TgAMA-1 molecules includes TgAMA-1 polypeptides, TgAMA-1 nucleic acids, and polypeptides, such as antibodies, that bind to TgAMA-1 polypeptides described herein.
- As used herein a “subject” shall mean a human or vertebrate animal including but not limited to a dog, cat, horse, cow, pig, sheep, goat, non-human primate (e.g. monkey), rabbit, rat, mouse, and bird. The term “subject” also includes cells collected from a human or animal, for example, blood collected for purposes such as, but not limited to, transfusions.
- As used herein, the term “cell” means a cell capable of being infected by, or suspected of being exposed to Toxoplasma. This may include cells from a subject and cells grown in culture. In some embodiments, a cell may be a control cell, which has not been exposed to toxoplasma. Cell types may include, but are not limited to, neuronal cells, ocular cells, erythrocytes, and intestinal cells.
- As used herein, the terms “toxoplasma infection”, and “toxoplasmosis” refer to infection by all members of the genus Toxoplasma. The application of the invention is described in many cases with reference to Toxoplasma gondii parasites, and is intended to include application of the methods to all strains Toxoplasma gondii. The methods of the invention are also envisioned to apply to treatment of toxoplasma parasite infections that result from other toxoplasma species.
- Particularly important subjects to which the present invention can be applied are subjects having been or suspected of having been exposed to toxoplasma, which includes subjects diagnosed with infection, exhibiting symptoms of infection, or having known or probable risk of exposure to toxoplasma infection.
- A subject may or may not exhibit symptoms of infection such as fever, swollen lymph glands, muscle aches, and pains. Methods to diagnose symptomatic and asymptomatic toxoplasma infection are known to those of ordinary skill in the medical arts and include, but are not limited to, blood tests for antibodies to the toxoplasma parasite. Brain scans by computerized tomography (CT scan) or magnetic resonance imaging (MRI scan) may also be used in the diagnosis of toxoplasma infection.
- Treatment as it relates to the invention may be prophylactic or therapeutic.
- Prophylactic and therapeutic treatment may involve administering a vaccine to induce/augment an immunoprotective response, or a polypeptide such as an antibody that binds TgAMA-1, to interfere with the toxoplasma parasite in the subject. Thus, in an important embodiment, the antibody to TgAMA-1 is administered to inhibit infection in a subject. As used herein, the term “reduce likelihood of infection” means to reduce or lower the level of entry into cells by the toxoplasma parasite. To “inhibit” or “block” may also mean to prevent entry into the cells by toxoplasma, but it is not necessary to prevent all entry to lessen or prevent the manifestation of disease.
- As used herein the term “TgAMA-1 polypeptides” means the polypeptide set forth as SEQ ID NO: 1, variants of the polypeptide set forth as SEQ ID NO: 1, and fragments of the polypeptide set forth as SEQ ID NO: 1. As noted above, the invention provides isolated TgAMA-1 polypeptides and TgAMA-1 binding polypeptides, such as antibodies, that bind to TgAMA-1 polypeptides. The invention also embraces functional variants, such as fragments, of the TgAMA-1 polypeptides. As used herein, a “functional variant” or “variant” TgAMA-1 polypeptide is a molecule that contains one or more modifications to the primary amino acid sequence of the TgAMA-1 polypeptide and retains the antigenic function of TgAMA-1. Modifications that create a TgAMA-1 polypeptide functional variant can be made, for example, to enhance a property of an TgAMA-1 polypeptide, such as peptide stability in an expression system or the antigenicity of the TgAMA-1 protein; or to provide a novel activity or property to a TgAMA-1 polypeptide, for example, to enhance detection. Modifications to a TgAMA-1 polypeptide can be made to a nucleic acid that encodes the peptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, substitution of one amino acid for another and the like. Modifications also embrace fusion proteins comprising all or part of the TgAMA-1 polypeptide amino acid sequence.
- The amino acid sequence of polypeptides may be of natural or non-natural origin, that is, they may comprise a TgAMA-1 polypeptide molecule or may comprise a modified sequence as long as the amino acid sequence retains the antigenic property of TgAMA-1. For example, TgAMa-1 polypeptides in this context may be fusion proteins of a TgAMA-1 polypeptide and unrelated amino acid sequences, synthetic peptides of amino acid sequences shown in SEQ ID NO: 1, peptides isolated from cultured cells that express TgAMA-1, and peptides coupled to nonpeptide molecules (for example in certain drug delivery systems, e.g., across a cell membrane, or detectable labels).
- An example, although not intended to be limiting, of a method with which antigenicity of a TgAMA-1 polypeptide can be tested involves in vivo testing in mice. One test involves the ability to enhance an antibody response to an antigen component of the TgAMA-1 antigen and/or the delayed-type hypersensitive (DTH) response, measured by an increase in footpad swelling after inoculation in the footpad of the test animal. These measurements can then be compared to corresponding measurements in control animals. Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation). Serum can be analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH response to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and or an increase in footpad swelling in the animals receiving the putative TgAMA-1 antigen as compared to the serum titer of the control animals, indicates that putative TgAMA-1 antigen is an antigenic TgAMA-1 polypeptide of the invention.
- If a functional variant involves a change to an amino acid if SEQ ID NO:1, the functional variant of the TgAMA-1 polypeptide may have conservative amino acid substitutions, i.e., substitutions which retain a property of the original amino acid such as charge, hydrophobicity, conformation, etc. Examples of conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.
- Other methods for identifying functional variants of SEQ ID NO:1 rely upon the development of amino acid sequence motifs to which potential epitopes may be compared. (See, e.g., published PCT application of Strominger and Wucherpfennig (US/96/03182)). In general, these methods rely upon the development of amino acid sequence motifs to which potential epitopes may be compared. Each motif describes a finite set of amino acid sequences in which the residues at each (relative) position may be (a) restricted to a single residue, (b) allowed to vary amongst a restricted set of residues, or (c) allowed to vary amongst all possible residues. For example, a motif might specify that the residue at a TgAMA-1 peptide position may be any one of the residues valine, leucine, isoleucine, methionine, or phenylalanine; that the residue at the second position must be histidine; that the residue at the third position may be any amino acid residue; that the residue at the fourth position may be any one of the residues valine, leucine, isoleucine, methionine, phenylalanine, tyrosine or tryptophan; and that the residue at the fifth position must be lysine.
- Sequence motifs for the TgAMA-1 polypeptide functional variants can be developed by analysis of the antigenic regions of the TgAMA-1 polypeptide disclosed herein. By providing a detailed structural analysis of the residues involved in the antigenicity of the TgAMA-1 polypeptide disclosed herein, one of ordinary skill in the art is enabled to make predictions of sequence motifs for antigenic regions of the TgAMA-1 polypeptides.
- Using these sequence motifs as search, evaluation, or design criteria, one of ordinary skill in the art is enabled to identify classes of peptides (functional variants of the TgAMA-1 polypeptide disclosed herein) which have a reasonable likelihood of being antigenic and/or to which binding polypeptides such as antibodies can be produced that inhibit parasite entry into cells. These peptides can be synthesized and tested for activity as described herein. Use of these motifs, as opposed to pure sequence homology (which excludes many peptides which are antigenically similar but quite distinct in sequence) or sequence homology with unlimited “conservative” substitutions (which admits many peptides which differ at critical highly conserved sites), represents a method by which one of ordinary skill in the art can evaluate peptides for potential application in the treatment of disease such as toxoplasma infection.
- The ability of the variant TgAMA-1 polypeptides to inhibit toxoplasma parasite entry into cells, is determined according to standard procedures. For example, the variant polypeptide can be contacted with the parasite, and standard procedures may be used to determine whether the parasite is inhibited in its ability to enter cells.
- Variant TgAMA-1 polypeptides include “fragments” of the polypeptide having SEQ ID NO:1. As used herein, a fragment has one or more amino acids fewer than the polypeptide set forth as SEQ ID NO:1. Those of ordinary skill in the art may apply no more than routine procedures to identify such fragments, in view of the disclosures provided herein.
- Variants and fragments as well as TgAMA-1 binding peptides such as antibodies may be tested for their ability to inhibit Toxoplasma activity. One method for inhibiting activity is by inhibiting entry of toxoplasma into cells. The ability to inhibit entry of toxoplasma parasite into cells with a TgAMA-1 polypeptide or binding polypeptide can be assessed using routine screening assays, e.g. by determining the level of TgAMA-1 mediated entry of Toxoplasma parasite into cells with and without the presence of the polypeptide. The ability of a putative TgAMA-1 polypeptide or binding polypeptide to out-compete toxoplasma parasite entry into cells can be determined by comparing the binding of the parasite TgAMA-1 to the cell in the presence and absence of the putative TgAMA-1 polypeptide or binding polypeptide. By comparing putative TgAMA-1 polypeptides or other binding peptides with the peptide of SEQ ID NO:1, additional polypeptides with increased parasite inhibiting properties can be identified.
- Nucleic acid sequences that code for a TgAMA-1 polypeptide or binding polypeptides, including allelic variants, are also a part of the invention. As used herein, an “isolated TgAMA-1 nucleic acid molecule” is a nucleic acid molecule that encodes an antigenic TgAMA-1 polypeptide. A TgAMA-1 nucleic acid molecule can be the nucleic acid molecule set forth as SEQ ID NO:2 or can be a fragment thereof. The TgAMA-1 nucleic acid molecules of the invention can also be variants of the nucleotide sequence set forth as SEQ ID NO:2. The invention also encompasses Watson-Crick complements of the foregoing TgAMA-1 nucleic acid molecules. The TgAMA-1 nucleic acids of the invention may encode fragments or variants of the polypeptide set forth as SEQ ID NO:1. In some embodiments, the TgAMA-1 nucleic acids of the invention do not encode the entire TgAMA-1 polypeptide of SEQ ID NO:1, but do include nucleotide sequences encoding the TgAMA-1 polypeptide fragments disclosed herein, or functional equivalents thereof.
- In screening for nucleic acids that encode a TgAMA-1 polypeptide or binding polypeptide of the invention, nucleic acid hybridization such as a Southern blot or a Northern blot may be performed under high stringency conditions, together with a labeled probe, for example, a 32P probe. The term “high stringency conditions” as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, or Current Protocols in Molecular Biology, F. M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary high stringency conditions include hybridization at 65° C. in hybridization buffer (3.5×SSC, 0.02% Ficoll, 0.02% Polyvinyl pyrolidone, 0.02% Bovine Serum Albumin, 25 mM NaH2PO4 (pH7), 0.5% SDS, 2 mM EDTA). SSC is 0.15M Sodium Chloride/0.015M Sodium Citrate, pH 7; SDS is Sodium Dodecyl Sulphate; and EDTA is Ethylene diaminetetraacetic acid. After hybridization, the membrane upon which the DNA is transferred can be washed, for example, at 2×SSC at room temperature and then at 0.1-0.5×SSC/0.1×SDS at temperatures up to 68° C. After washing the membrane to which DNA encoding a TgAMA-1 immunogenic polypeptide is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal.
- There are other conditions, reagents, and so forth that can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of nucleic acids encoding the TgAMA-1 polypeptide of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.
- The invention also includes the use of nucleic acid sequences which include alternative codons that encode the same amino acid residues of the TgAMA-1 polypeptide or binding polypeptide of the invention. For example, leucine residues can be encoded by the codons CUA, CUC, CUG, CUU, UUA and UUG. Each of the six codons is equivalent for the purposes of encoding a leucine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the leucine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, in vitro or in vivo, to incorporate a leucine residue. Similarly, nucleotide sequence triplets which encode other amino acid residues comprising the TgAMA-1 polypeptide include: GUA, GUC, GUG and GUU (valine codons); GGU, GGA, GGG, GGC (glycine codons); UAC and UAU (tyrosine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the native TgAMA-1 polypeptide encoding nucleic acids in codon sequence due to the degeneracy of the genetic code.
- The invention also provides modified nucleic acid molecules, which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as antigenicity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.
- For example, modified nucleic acid molecules that encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two, or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.
- It will also be understood that the invention embraces the use of the sequences in expression vectors, as well as to transfect host cells and cell lines. A host cell, as used herein, is any cell capable of expressing a peptide in the presence of appropriate expression vectors. Host cells include but are not limited to prokaryotic (e.g., E. coli), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells, plasmids in High Five™ Cells). Especially useful are insect cells as host cells for expression in the invention. An example of useful insect cells, although not intended to be limiting, are High Five™ insect cells (see Examples). Plants may also be used to express the TgAMA-1 vaccines of the invention. The expression vectors require that the pertinent sequence, i.e., those described supra, be operably linked to a promoter. Thus, the polypeptides of the invention may be produced in host cells and delivered to a subject.
- Alternatively, the peptides may be produced in vivo following administration of an expression vector with the TgAMA-1 nucleic acid to a subject. Delivery of expression vectors encoding the TgAMA-1 sequences in vivo and/or in vitro can be via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., Eur. J Immunol. 26(8):1951-1959, 1996). Recombinant vectors including viruses selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses such as NYVAC, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle, plasmids (e.g. “naked” DNA), bacteria (e.g. the bacterium Bacille Calmette Guerin, BCG), and the like can be used in such delivery. For example, the expression vectors can be administered in vivo to produce the antigen as a vaccine. Other viruses, expression vectors and the like which are useful in preparation of a vaccine antigen in vivo are known to one of ordinary skill in the art. Since nucleic acids have some adjuvant properties an antigen expressed in vivo from an expression vector may not require an additional adjuvant. One can test the TgAMA-1 molecule delivery systems in standard model systems such as mice to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.
- As used herein, a “vector” may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids, bacteria and virus genomes as disclosed herein, such as adenovirus, poxvirus and BCG. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β-galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.
- As used herein, a coding sequence and regulatory sequences are said to be “operably” joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5′ regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide. As noted above, some nucleic acids express only fragments of TgAMA-1 polypeptides that include antigenic fragments.
- The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5′ non-transcribed and 5′ non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5′ non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5′ leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.
- Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a TgAMA-1 polypeptide of the invention. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.
- Preferred systems for mRNA expression in mammalian cells are those such as pcDNA3.1 (available from Invitrogen, Carlsbad, Calif.) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1α, which stimulates efficiently transcription in vitro. The plasmid is described by Mishizuma and Nagata (Nuc. Acids Res. 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (Mol. Cell. Biol. 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (J. Clin. Invest. 90:626-630, 1992). The use of the adenovirus to express proteins for immunization is disclosed by Wamier et al., in intradermal injection in mice for immunization against P1A (Int. J Cancer, 67:303-310, 1996).
- The invention also embraces expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of at least two of the previously discussed materials. Other components may be added, as desired.
- In another aspect of the invention transgenic non-human animals comprising the expression vector of the invention are provided. Such transgenic animals are capable of expressing a variable level of TgAMA-1 polypeptide. In some embodiments, a mammal is genetically modified to produce TgAMA-1 in its milk Techniques for performing such genetic modifications are described in U.S. Pat. No. 6,013,857, issued Jan. 11, 2000 for :Transgenic Bovines and Milk from Transgenic Bovines.” The genome of the transgenic animal is modified to comprise a transgene comprising a DNA sequence encoding TgAMA-1 operably linked to a mammary gland promoter. Expression of the DNA sequence results in the production of TgAMA-1 in the milk. TgAMA-1 may then be isolated from milk obtained from the transgenic mammal (e.g. using a column comprising an antibody which binds to TgAMA-1). The transgenic mammal is preferably a bovine species.
- The invention also encompasses peptides that bind to TgAMA-1, refereed to herein as TgAMA-1 polypeptides or peptides. TgAMA-1 binding polypeptides include but are not limited to anti-TgAMA-1 antibodies including polyclonal and monoclonal antibodies, antibody fragments, and other non-antibody peptides. Antibodies useful in the methods of the invention include but are not limited to monoclonal antibody B3.90, which binds to TgAMA-1 and is described herein, and polyclonal antibodies such as UVT59, which is described herein.
- The TgAMA-1 binding polypeptides (e.g. anti-TgAMA-1 antibodies) of the invention selectively bind to TgAMA-1 polypeptides and in some embodiments inhibit entry of Toxoplasma gondii or other toxoplasma parasite into cells. Such TgAMA-1 binding polypeptides are prepared by standard methods.
- In view of the foregoing, the invention also permits the artisan to treat a subject having a toxoplasma infection or at risk of developing a toxoplasma infection. Treatments include administering TgAMA-1 polypeptides, optionally in the form of a vaccine or a TgAMA-1 binding polypeptide, including the anti-TgAMA-1 antibodies of the invention disclosed herein.
- In certain embodiments, the TgAMA-1 polypeptides and anti-TgAMA-1 antibodies of the invention are used to produce antibodies (“anti-TgAMA-1 antibodies”) using standard techniques well known to the art. Standard reference works setting forth the general principles of antibody production include Catty, D., Antibodies, A Practical Approach, Vol. 1, IRL Press, Washington D.C. (1988); Klein, J., Immunology: The Science of Cell-Non-Cell Discrimination, John Wiley and Sons, New York (1982); Kennett, R., et al., Monoclonal Antibodies Hybridoma, A New Dimension In Biological Analyses, Plenum Press, New York (1980); Campbell, A., Monoclonal Antibody Technology, in Laboratory Techniques and Biochemistry and Molecular Biology, Vol. 13 (Burdon, R. et al. EDS.), Elsevier Amsterdam (1984); and Eisen, H. N., Microbiology, third edition, Davis, B. D. et al. EDS. (Harper & Rowe, Philadelphia (1980). See also, U.S. Pat. No. 5,101,017, issued Mar. 31, 1992 to Rubinstein, et al., entitled, “Antibodies for providing protein against P. vivax malaria infection,” which also reports the preparation of anti-idiotypic antibodies for treating infectious disease. References that report vaccine approaches for treating malaria disease, which is also a parasitic infection, include: U.S. Pat. No. 6,066,623, issued to Hoffinan, et al., entitled “Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines”; and U.S. Pat. No. 6,120,770, issued to Adams et al., entitled “Plasmodium proteins useful for preparing vaccine compositions.”
- The antibodies of the present invention are prepared using any of a variety of methods, including administering the TgAMA-1 polypeptides of the invention, antibodies selective for the foregoing, and the like to an animal to induce monoclonal or polyclonal antibodies. The production of monoclonal antibodies is according to techniques well known in the art.
- Non-limiting examples of supports for affinity-separation of antibodies, including monoclonals, include the following: activated Sepharose, activated cellulose and activated Sephadex. “Activated” refers to the creation, on the insoluble material, of reactive chemical groups that will form covalent linkages with the antibody molecules when incubated together under appropriate conditions. Typically, reactive groups are introduced into the insoluble substrate by the action of cyanogen bromide (CNBr) at high pH.
- Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W. R. (1986) The Experimental Foundations of Modem Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc′ and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc′ region has been enzymatically cleaved, or which has been produced without the pFc′ region, designated an F(ab′)2 fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.
- Within the antigen-binding portion of an antibody, there are complementary determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.
- It is now well established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of “humanized” antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc′ regions to produce a functional antibody. See, e.g., U.S. Pat. Nos. 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Accordingly, humanized anti-TgAMA-1 antibodies, particularly those that selectively bind to SEQ ID NO:1, and the use of such antibodies (e.g., to provide passive immunity to a subject) are embraced with the inventions disclosed herein.
- For example, PCT International Publication Number WO92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as “chimeric” antibodies.
- Thus, the present invention also provides for F(ab′)2, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab′)2 fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and
- chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies and human monoclonal antibodies, such as those produced by mice having functional TgAMA-1 loci.
- Such antibodies also may be used to identify tissues expressing protein or to purify protein. Antibodies, also may be coupled to specific labeling agents for imaging or to anti-infectious agents, toxins such as ricin, other cytostatic or cytolytic drugs, and so forth, for therapeutic purposes.
- The invention also involves the use of anti-idiotypic antibodies. By using monoclonal antibodies that interact with TgAMA-1 polypeptide, it is also possible to produce anti-idiotypic antibodies which can be used to screen other molecules to identify whether the other molecule has the same binding specificity as the monoclonal antibody. Such anti-idiotypic antibodies can be produced using well-known hybridoma techniques (Kohler and Milstein, Nature, 256:495, 1975). An anti-idiotypic antibody is an antibody which recognizes unique determinants present on the known monoclonal antibodies. These determinants are located in the hypervariable region of the antibody. It is this region which binds to a given epitope and, thus, is responsible for the specificity of the antibody. An anti-idiotypic antibody can be prepared by immunizing an animal with a monoclonal antibody. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing monoclonal antibodies and produce an antibody to these idiotypic determinants. By using the anti-idiotypic antibodies of the immunized animal, which are specific for the monoclonal antibodies of the invention, it is possible to identify other clones with the same idiotype as the monoclonal antibody used for immunization. Idiotypic identity between monoclonal antibodies of two cell lines demonstrates that the two monoclonal antibodies are the same with respect to their recognition of the same epitopic determinant. Thus, by using anti-idiotypic antibodies, it is possible to identify other hybridomas expressing monoclonal antibodies having the same epitopic specificity.
- It is also possible to use the anti-idiotype technology to produce monoclonal antibodies which mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the image of the epitope bound by the first monoclonal antibody.
- When administered, the therapeutic compositions of the present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.
- The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The characteristics of the carrier will depend on the route of administration.
- The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intranasal, intracavity, subcutaneous, intradermal, or transdermal.
- Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
- The invention involves the use of various materials disclosed herein to “immunize” subjects or as “vaccines.” A “vaccine’ as used herein is an antigen in a pharmaceutical formulation and optionally includes an adjuvant. As used herein, “immunization” or “vaccination” means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen. Generally accepted animal models can be used for testing of immunization against toxoplasma using a toxoplasma antigen polypeptide or nucleic acid. For example, toxoplasma parasite can be introduced into a mouse to create the disease, and one or more toxoplasma antigen can be delivered by the methods described herein. The effect on the toxoplasma disorder can be assessed as a measure of the effectiveness of the toxoplasma antigen immunization. Of course, testing of the foregoing animal model using more conventional methods for immunization include the administration of one or more toxoplasma antigen polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response. Methods for immunization, including formulation of a vaccine composition and selection of doses, route of administration and the schedule of administration (e.g. primary and one or more booster doses), are well known in the art. The tests also can be performed in humans, where the end point is to test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen, to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing the antigen and so forth.
- As part of the immunization compositions, one or more TgAMA-1 polypeptides are administered optionally with one or more adjuvants to induce an immune response or to increase an immune response. An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response. Adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-analyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-analanine-2-(1′-2′dipalmitoyl-sn-glycero-3-hydroxyphosphroyloxy)-ethylamine, monophosphoryl lipid A; saponins (QS21; DQS21); QS-7, QS-17, QS-18, and QS-L1; incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; vitamin E, oil emulsions, and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol.
- Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art.
- In some embodiments, the polypeptides are administered mixed with a combination of DQS21I/MPL. The ratio of DQS21 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1. Typically for human administration, DQS21 and MPL will be present in a vaccine formulation in the range of about 1 μg to about 100 μg. Other adjuvants are known in the art and can be used in the invention (see, e.g. Goding, Monoclonal Antibodies: Principles and Practice, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.
- Other agents which stimulate the immune response of the subject can also be administered to the subject. For example, other cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many other cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-1 2) which has been shown to enhance the protective effects of vaccines (see, e.g., Science 268: 1432-1434, 1995), GM-CSF and IL-18. Thus cytokines can be administered in conjunction with antigens and adjuvants to increase the immune response to the antigens.
- In some embodiments of the invention, the vaccine is a proteosome vaccine. Proteosomes are useful for immunopotentiation by rendering peptides immunogenic and enhancing the immunostimulating properties of larger peptides, proteins, and protein fragments. Methods for preparing proteosomes include, but are not limited to, preparation from meningococci, as described in U.S. Pat. No. 5,726,292, the contents of which is hereby incorporated in its entirety.
- The preparations of the invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, stimulates the desired response. In the case of treating an infectious disease such as toxoplasma, the desired response is inhibiting the onset, stage or progression of the disease or infection. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently, or preventing infection.
- The TgAMA-1 molecule dosage may be adjusted by the individual physician or veterinarian, particularly in the event of any complication. A therapeutically effective amount typically varies from 0.01 mg/kg to about 1000 mg/kg, preferably from about 0.1 mg/kg to about 200 mg/kg, and most preferably from about 0.2 mg/kg to about 20 mg/kg, in one or more dose administrations daily, for one or more days.
- The absolute amount will depend upon a variety of factors, including the material selected for administration, whether the administration is in single or multiple doses, and individual patient parameters including age, physical condition, size, weight, and the stage of the disease. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.
- In one embodiment, the therapeutically effective amount of the TgAMA-1 molecule is that amount effective to inhibit toxoplasma entry into cells. Such inhibition can be determined using standard assays as described above. In other embodiments a therapeutically effective amount is that amount effective to induce an immune response against the parasite. Measurements of acute toxoplasma infection, including isolation of the parasite from either blood or other body fluids after subinoculation of the body fluid into the peritoneal cavity of mice can be used to assess the levels of parasites remaining in the blood after exposure. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998). If no parasites are found in the mouse's peritoneal fluid, its anti-Toxoplasma serum titer can be evaluated 4 to 6 weeks after inoculation. The presence of Toxoplasma gondii in a subject's body fluid represents an acute infection, and the presence of Toxoplasma gondii in tissue biopsies is an indication only of the presence of tissue cysts and not acute toxoplasmosis. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998). Additional methods of diagnosis and assessment of chronic and acute toxoplasma infection are known to those of skill in the art.
- In addition, diagnosis of an acute Toxoplasma gondii infection by detection of the simultaneous presence of IgG and IgM antibody to Toxoplasma in the subject's serum. The presence of circulating IgA suggests an acute infection. The Sabin-Feldman dye test, the indirect fluorescent antibody test, and the enzyme-linked immunosorbent assay (ELISA) all satisfactorily measure circulating IgG antibody to Toxoplasma. Positive IgG titers (>1:10) can be detected as early as 2 to 3 weeks after infection. These titers usually peak at 6 to 8 weeks and decline slowly to a new baseline level that persists for life. The methods currently available for this determination are the double-sandwich IgM-ELISA and the IgM-immunosorbent assay (IgM-ISAGA). The double-sandwich IgA-ELISA is more sensitive than the IgM-ELISA for detecting congenital infection in the fetus and newborn. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998).
- In addition to the diagnostic tests described above, clinical features of toxoplasma infection can be monitored for assessment of infection. Theses features include, but are not limited to: assessment of the presence of eye lesions, brain lesions, and brain inflammation. Such assessment can be with methods known to one of ordinary skill in the art, such as ophthalmologic testing, CSF evaluation, and radiologic studies. (see Harrison's Principles of Internal Medicine, 14/e, McGraw Hill Companies, New York, 1998).
- These types of tests, as well as others known to those of ordinary skill in the medical arts, may be used to assess the toxoplasma infection status of a subject and to evaluate a therapeutically effective amount of TgAMA-1 molecule or TgAMA-1 binding polypeptides administered. A first determination of toxoplasma infection may be obtained using one of the methods described above, and a subsequent determination of infection can be done and a comparison of the infection levels may be used to assess the effectiveness of TgAMA-1 molecule or TgAMA-1 binding polypeptides administration as a prophylactic or a treatment of the toxoplasma infection. Absence of a toxoplasma infection may be an indication for prophylactic intervention by administering TgAMA-1 molecules or TgAMA-1 binding polypeptides to prevent toxoplasma infection.
- The TgAMA-1 molecules and TgAMA-1 binding polypeptides may be administered alone, in combination with each other, and/or in combination with other anti-toxoplasma drug therapies. Antitoxoplasma agents (for treatment and/or prophylaxis) that may be administered with TgAMA-1 molecules or TgAMA-1 binding polypeptides may include, but are not limited to: pyrimethamine plus either sulfadiazine or clindamycin; trimethoprim; protein synthesis inhibitors such as clindamycin, chlortetracycline, and azithromycin;. purine synthesis inhibitors such as arprinocid; atovaquone; spiramycin plus prednisone; Dapsone (diaminodiphenyl sulfone); macrolides including roxithromycin, clarithromycin, and azithromycin; and phenytoin.
- The above-described drug therapies are well known to those of ordinary skill in the art and are administered by modes known to those of skill in the art. The drug therapies are administered in amounts that are effective to achieve the physiological goals (to reduce toxoplasma infection, and/or reduce toxoplasma titer in a subject), in combination with the TgAMA-1 molecules of the invention. Thus, it is contemplated that the drug therapies may be administered in amounts which are not capable of preventing or reducing the physiological consequences of the toxoplasma infections when the drug therapies are administered alone, but which are capable of preventing or reducing the physiological consequences of toxoplasma infection when administered in combination with the TgAMA-1 molecules of the invention.
- The vaccine formulations of the invention may be administered to confer immunity to a subject at risk of exposure to toxoplasma, which thereby prevents, reduces the severity of or delays the onset of a subsequent Toxoplasma infection. Alternatively, the vaccines may be administered during an ongoing Toxoplasma infection to improve the effectiveness of the host's response to the infections Toxoplasma organism.
- The invention also provides a pharmaceutical kit comprising one or more containers comprising one or more of the TgAMA-1 molecules and/or antibodies of the invention and or formulations of the invention. The kit may also include instructions for the use of the one or more TgAMA-1 molecules and/or antibodies of the invention for the treatment of toxoplasma infection.
- Procedure
- Parasite Culture
- T. gondii tachyzoites (RH strain, unless otherwise indicated) were cultured in human foreskin fibroblasts as previously described [5] and filtered through a 10 μm polycarbonate filter (Poretics, Livermore Calif.) prior to use.
- Antibodies
- MAbs: MAb B3.90 (against TgAMA-1) and A3.2 (against GRA8) were generated as described [3, 6] and purified by ion exchange and gel filtration chromatography [7]. Ascites fluid containing MAb 6D10 (against MIC2) was prepared as described [1]. Ascites fluid containing MAb Tg49 (against ROP1) was generously provided by Joseph Schwartzman (Dartmouth College, Hanover N.H.). MAb 40-1a (against E. coli β-galactosidase) was developed by J. R. Sanes and obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Department of Biological Sciences, Iowa City Iowa) as a hybridoma supernatant.
- Polyclonal antibody UVT59: A synthetic peptide corresponding to residues 496-515 of TgAMA-1 (acetyl-EFQSDRGARKKRPSDLMQEAC-amide (SEQ ID NO:3)) was coupled to keyhole limpet hemocyanin using the Imject Maleimide Activated mcKLH Kit (Pierce, Rockford Ill.). The peptide-carrier conjugate was used to generate rabbit polyclonal antisera (Cocalico Biologicals Inc., Reamstown Pa.); serum titers were determined by western blot and immunofluorescence microscopy. Synthetic peptide coupled to agarose using the SulfoLink Kit (Pierce) was used to affinity purify AMA-I-specific antibody UVT59 from total serum as recommended by the manufacturer, except that 0.01 vol of stock protease inhibitors (aqueous stock contains 2 mg/ml aprotinin, 2 mg/ml leupeptin, 16 mg/ml benzamidine, and 5 mg/ml 4-(2-aminoethyl)-phenylsulfonylfluoride; DMSO stock contains 5 mg/ml pepstatin) were added to the serum before applying it to the peptide column.
- Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blotting
- Proteins were resolved by SDS-PAGE in the presence (reducing) or absence (non-reducing) of 5% (v/v) β-mercaptoethanol and western blotted as described[3], using MAb B3.90, MAb 6D10, MAb 40-1a and polyclonal serum UVT 59 at dilutions of 23.2 μg/ml, 1/5000 (v/v), 1/100 (v/v), and 1/10,000 (v/v), respectively. Where indicated, blots were stripped by sequential incubation in PBS (2 changes, 5 min each), 4% (w/v) trichloroacetic acid (2 changes, 10 min each), and PBS (2 changes, 5 min each). Stripped blots were either reblocked and probed with a different antibody or exposed directly to X-ray film.
- Triton X-114 (TX-114) Phase Partitioning
- TX-114 phase partitioning of total parasite extracts was carried out as previously described [6]. After partitioning, the detergent phase was diluted to the original extract volume (4×107 parasite equivalents/ml) with 50 mM Tris-HCl, pH 7.4 and 100 mM NaCl, supplemented with 3.0 U/ml Bacillus cereus phosphatidylinositol-specific phospholipase C (PI-PLC; Molecular Probes, Eugene Oreg.) and sequentially incubated for 5 min on ice, 35 min at 37° C. and 5 min on ice. The PI-PLC-treated detergent phase was then subjected to 2 additional rounds of phase partitioning, and analyzed by SDS-PAGE/western blotting.
- Immunoaffinity Purification and Sequence Analysis
- MAb B3.90 was covalently cross-linked to Affi-Gel Protein A-conjugated agarose (BioRad, Hercules Calif.) as previously described [8]. Approximately 2.5 mg of IgG was coupled per 1 ml of resin. Parasites were washed twice in phosphate-buffered saline (PBS), pH 7.4 and extracted for 45 min on ice in EXTR buffer (0.5% [v/v] Triton X-100 (TX-100), 50 mM Tris, pH 7.4, 100 mM NaCl) supplemented with 0.01 volumes of the aqueous and DMSO protease inhibitor stocks. The extracts were centrifuged at 14,000×g for 5 min at 4° C. to remove insoluble material; the protein concentration of the supernatant was determined using the DC Protein Assay (BioRad). Extract (5 ml, 3.5 mg total protein) was added to 450 μL of antibody-conjugated beads (prewashed three times with EXTR buffer) and rotated gently for 2 h at 4° C., followed by 4 washes (batchwise) with EXTR buffer. Bound antigen was eluted from the washed beads using two sequential incubations with 400 μl of non-reducing SDS-PAGE sample buffer for 10 min at 100° C. The pooled eluate was concentrated 10-fold using a Centricon RC/YM-30 centrifugal filter device (30,000 MWCO; Millipore, Bedford Mass.) and subjected to SDS-PAGE. The gel was stained for 30 min with 0.1% (w/v) Coomassie R-250 in 50% (v/v) methanol, 10% (v/v) acetic acid and destained for 1 h in 10% (v/v) methanol and 7.5% (v/v) acetic acid. The purified antigen was cut out of the gel, digested with trypsin, and analyzed at the Harvard Microchemistry Facility (Cambridge Mass.) by microcapillary reverse-phase HPLC nano-electrospray tandem mass spectrometry (μLC/MS/MS) on a Finnigan LCQ quadropole ion trap mass spectrometer. The fragmentation spectra were correlated with known sequences using previously described algorithms [9, 10].
- Immunofluorescence
- Methanol fixation. Parasites were attached to the surface of glass coverslips using Cell Tack (Becton Dickinson, Bedford Mass.) as described [3]. They were washed twice with PBS, pH 7.4, at 4° C. and fixed in 100% methanol for 5 min at −20° C. All subsequent incubations were carried out at 4° C. The fixed parasites were washed 4 times in PBS, blocked for 10 min in PBS containing 0.5% (w/v) bovine serum albumin (PBS-BSA), and incubated for 45 min in primary antibody diluted in PBS-BSA as follows: B3.90, 11.5 μg/ml; A3.2, 0.5 μg/ml; 6D10, 1/50 (v/v); Tg49, 1/100 (v/v); affinity purified UVT59, 12.5 μg/ml. They were then washed 3 times with PBS, incubated for 30 min in PBS-BSA containing either 1.5 μg/ml Alexa546-conjugated goat anti-mouse IgG (Molecular Probes, Eugene Oreg.) or 0.9 μg/ml Alexa546-conjugated goat anti-rabbit IgG (Molecular Probes), and washed three times with PBS. For dual label immunofluorescence, parasites were then incubated for 45 min in PBS-BSA containing MAb B3.90 which had been directly conjugated to Alexa488 using an Alexa488 Protein Labeling kit (Molecular Probes). The labeled parasites were washed 5 times in PBS and mounted on glass slides for observation.
- Formaldehyde/glutaraldehyde fixation. Samples were processed as above, except that the methanol fixation step was replaced by 30 min at 4° C. in 2.5% (v/v) formaldehyde, 0.025% (v/v) glutaraldehyde. Where indicated, samples were permeabilized by including 0.1% (v/v) TX-100 in the PBS-BSA block and in the primary antibody incubation.
- Unfixed/unpermeabilized suspension assay. Tachyzoites were washed twice in PBS, pH 7.4 by centrifugation for 4 min at 1000×g (23° C) and incubated for 10 min at 4° C. in PBS-BSA, followed by 1 hr at 4° C. in PBS-BSA containing primary antibody, diluted as above. The labeled cells were washed 3 times in PBS, post-fixed 25 min at 4° C. in PBS containing 2.5% (v/v) formaldehyde and 0.025% (v/v) glutaraldehyde, washed 3 times in PBS, incubated with fluorescently conjugated secondary antibody as above, washed 5 times in PBS and mounted on glass slides in PBS for observation.
- Microscopy. Samples were observed on a Nikon Eclipse E400 fluorescence microscope using Nikon filter cube XF100 (excitation 455-495 nm, emission 515-560 nm) for Alexa488 and filter cube XF102 (excitation 535-590 nm, emission 605-710 nm) for Alexa546. No Alexa488 fluorescence was detectable using the XF102 filter, and no Alexa546 fluorescence was detectable using the XF100 filter. Digitized images were obtained using either a VE1000SIT camera (Dage-MTI, Michigan City Ind.) with an LG-3 framegrabber and Scion Image v 1.6 software (Scion Corp., Frederick Md.) or a SpotRT monochrome camera driven by Spot v.3.01 (AppleEvent) software (Diagnostic Instruments Inc., Sterling Heights Mich.).
- Immunoelectron Microscopy
- Cryoimmunoelectron microscopy was performed as previously described [6], using MAb B3.90 (25 ug/ml) as primary antibody. No immunogold labeling was observed when primary antibody was omitted.
- Secretion Assays
- Tachyzoites (2F strain, constitutively expressing cytoplasmic β-galactosidase [generous gift of David Sibley]) were washed twice in DMEM+20 mM HEPES, pH 7.0 (4 min, 1000×g, 23° C.), and resuspended in 4 ml polystyrene round bottom tubes at a concentration of 2×108 tachyzoites/ml. The suspension was incubated for various times at 37° C. or treated for 15 min at 23° C. with either 1.0% (v/v) DMSO or 20 μM BAPTA-AM (1.0% [v/v] DMSO final), followed by 2 min at 37° C. with 200 nM A23187 (1.0% [v/v] DMSO final) or 1.0% ethanol. Cells were pelleted (4 min, 1000×g, 4° C.) and dissolved in SDS-PAGE sample buffer. Supernatants were recentrifuged (4 min, 1000×g, 4° C.) and dissolved in sample buffer. The samples were incubated for 10 min at 100° C. and analyzed by SDS-PAGE/western blotting. Gels to be probed with either Mab B3.90 or antipeptide antiserum UVT59 were run under non-reducing conditions; blots to be probed with Mab 6D10 were run under reducing conditions. The extent of parasite lysis was determined by measuring the levels of β-galactosidase in the supernatant, as previously described [4].
- Subcellular Fractionation
- A subcellular fraction enriched in micronemes was prepared as described [2] except that the microneme fraction was extracted with 0.01% saponin to recover the micronemal contents.
- Labeling Parasites with 125I-iodonaphthylene azide (125I-INA)
- INA was synthesized from 5-aminonaphthalene-1-azide [11] and labeled with 125I (Lofstrand Laboratories, Gaithersburg, Md.) to a specific activity of ˜1 mCi/μmol. Filtered parasites from a freshly lysed monolayer of human foreskin fibroblasts were washed twice (1000×g, 4 min, 23° C.) with IM-PR (phenol-red deficient DMEM+20 mM HEPES, pH 7.0), and resuspended in IM-PR to a concentration of 2×108 tachyzoites/ml. Reduced glutathione was added to a concentration of 15 mM. All subsequent manipulations were performed in low light. 125I-INA (DMSO stock, ˜1 mCi/ml) was added to the parasite suspension to a final concentration of 1.0% v/v DMSO. The suspension was added to an equal vol of IM-PR (37° C.) containing 2.0% (v/v) ethanol in a 4 ml polystyrene round bottom tube. The cells were incubated for 2 min at 37° C., pelleted (4 min, 1000×g, 4° C.), resuspended in IM-PR, and irradiated for 5 min at 4° C. using a shortwave ultraviolet lamp (UVP Inc., San Gabriel Calif.; Model UV6-54, 254 nm) at a distance of 2 cm. The parasites were pelleted (14,000×g, 5 min) and extracted (1.4×106 tachyzoites/μl, 45 min, 4° C.) in 0.5% (v/v) TX-100, 50 mM Tris pH7.4, 100 mM NaCl, 2 mM EDTA supplemented with 0.01 volumes of the aqueous and DMSO protease inhibitor stocks. Affinity purified polyclonal antibody UVT59 was coupled to agarose beads and 36 μl of beads were used to immunoprecipitate TgAMA-1 from 75 μl of the TX-100 extract as described above. Immunoprecipitated proteins eluted from the beads in 36 μl of sample buffer were analyzed by SDS-PAGE under reducing conditions and western blotted with antipeptide antiserum as described above. The membrane was then stripped as described above and exposed to BioMax MS X-ray film (Eastman Kodak, Rochester N.Y.) at −70° C.
- Results
- Identification and Initial Characterization of TgAMA-1
- In experiments designed to identify novel, non-GPI-linked apical or peripheral tachyzoite antigens [3, 6], a MAb (B3.90) was generated that reacts with a 63 kDa protein on western blots of total tachyzoite extracts, and shows both apical and peripheral localization by immunofluorescence (see below). MAb B3.90 recognizes a 63 kDa antigen on western blots of non-reduced tachyzoite extracts. No bands were detected when the samples were treated with β-mercaptoethanol prior to SDS-PAGE.
- In TX-114 phase partitioning experiments, the 63 kDa antigen is recovered in the detergent phase both before and after treatment with PI-PLC, consistent with the behavior of a non-GPI-linked, transmembrane protein. For the TX-114 phase partitioning tachyzoites (Total) were extracted on ice in a buffer containing 0.5% (v/v) TX-114 and the cleared extract (TX-114 Soluble) was separated into aqueous (Aqueous I) and detergent (Detergent I) phases at 37° C. The detergent phase was incubated with PI-PLC and partitioned again into aqueous (AqueousII) and detergent (DetergentII) phases. Fractions were analyzed by SDS-PAGE/western blotting (4×105 parasite equivalents loaded per lane); the 60 kDa region of a western blot was probed with MAb B3.90. SAG1, the major GPI-linked protein of the tachyzoite, quantitatively shifted from the Detergent I fraction to the Aqueous II fraction under these conditions, confirming the effectiveness of the PI-PLC treatment.
- The 63 kDa antigen was purified by immunoaffinity chromatography using MAb B3.90. Tryptic peptides prepared from the purified protein were analyzed by tandem microcapillary reverse-phase HPLC/ion trap mass spectrometry. The resultant fragmentation spectra unambiguously identified the 63 kDa antigen as Genbank entry AF010264 (deposited by Hehl, Oretga-Barria and Boothroyd), the Toxoplasma homolog (TgAMA-1) of Plasmodium AMA-1. Multiple sequence alignment of TgAMA-1 with AMA-1 from the different Plasmodium species revealed significant homology across all species. Most strikingly, 12 of the 16 cysteines whose positions are invariant among Plasmodium species are also conserved in TgAMA-1. These cysteines are known to form intramolecular disulfide bridges in Plasmodium AMA-1 [12]. Other notable features in the TgAMA-1 primary sequence are a putative signal peptide, with a predicted cleavage site between residues 22 and 23 (ASG-LS), and a potential transmembrane domain between residues 457 and 476.
- TgAMA-1 is a Microneme Protein
- To localize TgAMA-1 in T. gondii, we performed dual label immunofluorescence microscopy on free tachyzoites using MAb B3.90 and antibodies against known microneme (MIC2), rhoptry (ROP1), or dense granule (GRA8) antigens. In permeabilized parasites, TgAMA-1 was found in a cap-like distribution at the apical end of the tachyzoite. This distribution is indistinguishable from that of MIC2, but distinctly different from that of GRA8 or ROP1, suggesting that TgAMA-1 resides in the micronemes of T. gondii tachyzoites. Immunoelectron microscopy with MAb B3.90 supports this conclusion, as does the enrichment of TgAMA-1 in a partially purified microneme fraction.
- Proteolytic Processing and Secretion of TgAMA-1
- Four of the five previously identified microneme proteins (MIC1, MIC2, MIC4, MIC5) are constitutively secreted from the tachyzoite at a low basal rate at 37° C. [2, 4, 13]. In the case of MIC2, secretion is coincident with specific proteolytic processing of the protein [14, 15]. To determine if TgAMA-1 behaves similarly, tachyzoites were incubated at 37° C. in culture medium for various times, the cells were centrifuged, and assayed by western blot to determine the amount of TgAMA-1 released into the supernatant vs. the amount retained in the cell pellet. A 53-k′)a fragment of TgAMA-1 was found to be constitutively secreted into the supernatant in a time-dependent manner.
- The amount of TgAMA-1 or MIC2 released from live parasites into the culture supernatant after 0 m, 10 m, 30 m, 60 m, or 120 m at 37° C. was determined by western blotting is5 with either NMb B3.90 (TgAMA-1) or 6D10 (MIC2). The estimated molecular masses of the secreted and cellular forms of TgAMA-1 were 53 and 63 kDa, respectively. The estimated molecular masses of full-length and processed forms of MIC2 are 115 kDa and 95-100 kDa, respectively [14]. The amount of TgAMA-1 (MAb B3.90) or MIC2 (MAb 6D10) released into the culture supernatant after a 2 minute incubation at 37° C. in the presence of: DMSO (DMSO control) was determined.; B-A23187 (A23187, following BAPTA-AM pretreatment); B-ETOH (ethanol, following BAPTA-AM pretreatment); A23187 (A23187, no BAPTA-AM pretreatment); or ETOH (ethanol, no BAPTA-AM pretreatment), were detected by western blotting.
- The full-length 63 kDa form, but no detectable amount of the 53-kDa fragment, was 25 found to remain associated with the cell pellet. More than 33% of the total TgAMA-1 was found to be secreted into the supernatant in the form of the 53-kDa fragment after 120 min at 37° C., as estimated by comparison to serial loadings of total parasite extracts. The extent of non-specific parasite lysis under these conditions was determined to be less than 2%, based on the release of soluble β-galactosidase [4]. Thus, TgAMA-1 appears to be constitutively processed and secreted from the parasite at 37° C.
- The secretion of the previously identified MIC proteins (and processing of MIC2) is enhanced by treatments which elevate intracellular calcium, including incubation with ethanol or the calcium ionophore A23187 [4, 15]. The secretion of the 53-kDa fragment of TgAMA-1 was also found to be dramatically enhanced following a 2-min treatment with ethanol or ionophore A23187 this enhanced secretion was abrogated by pretreating the parasites with the membrane permeant calcium chelator, BAPTA-AM.
- Localization and Secretion of the N- and C-Terminal Fragments of TgAMA-1
- While full-length TgAMA-1 requires detergent for its solubilization, the 53-kDa secreted form of the protein was recovered in the low speed supernatant in the secretion assays, in the absence of added detergent. To test the hypothesis that the secreted fragment represents 53-kDa of the protein N-terminal to the putative transmembrane domain and that MAb B3.90 reacts with an epitope within this portion of TgAMA-1, we generated a rabbit polyclonal antiserum against a synthetic peptide corresponding to 20 amino acids C-terminal to the transmembrane domain. The anti-peptide antibody was found to be highly specific, recognizing a major 63 kDa band on western blots of tachyzoite extracts run under non-reducing condition (67 kDa under reducing conditions) and a minor band of approximately 12 kDa. The anti-peptide antiserum UVT59 recognized a major antigen of 63 kDa, and a minor antigen of 12 kDa on western blots of non-reduced tachyzoite extracts. The 63 kDa UVT59-reactive band migrated at 67 kDa under reducing conditions. The 12 kDa band was not detected on identical blots probed with MAb B3.90. Proteins of 67 and 12 kDa were also immunoprecipitated with the anti-peptide antibody, and are labeled in intact parasites with the photoactivatable hydrophobic probe 125I-INA. Labeling of a protein with 125I-INA provides evidence that a portion of the protein is embedded within a lipid bilayer [11].
- The immunofluorescence pattern seen with the anti-peptide antibody was different from that seen with MAb B3.90. In methanol-permeabilized parasites, both antibodies showed a strong concentration of TgAMA-1 at the apical end of the parasite, superimposed on a fainter peripheral distribution. A similar pattern was seen in parasites fixed with formaldehyde/glutaraldehyde and permeabilized with TX-100 using MAb B3.90, but under these fixation/permeabilization conditions the anti-peptide antibody labeled the periphery of the parasite with little concentration at the apical end. Most strikingly, 10-50% of live tachyzoites showed peripheral labeling of varying intensity with MAb B3.90, whereas no staining was seen with the anti-peptide antibody.
- Taken together, these data suggest that TgAMA-1 is proteolytically processed into at least two fragments: a 53 kDa N-terminal fragment which is released from the parasite and contains the epitope for MAb B3.90, and a 12 kDa C-terminal fragment which is recognized by the anti-peptide antibody and which remains associated with the parasite, presumably via its transmembrane domain. Secretion assay results are consistent with this model: the anti-peptide antibody recognizes full length TgAMA-1 and the 12 kDa peptide in the cell pellet but detects nothing in the supernatant after either 60 minutes of constitutive secretion or 2 minutes of ethanol/A23187-induced secretion. No soluble fragments of TgAMA-1 were detected with antipeptide antibody UVT59 in secretion assays. Parasites were preincubated for 2 min with or without BAPTA-AM, followed by a 2 min incubation in the presence of 1% ethanol. TgAMA-1 released into the assay supernatant was detected by western blotting with MAb B3.90; the blot was then stripped and reprobed with anti-peptide antibody UVT59. Significant ethanol-induced secretion of the 53 kDa peptide was observed with MAb B3.90; neither this fragment nor any other was detected in the supernatant using antipeptide antibody UVT59.
- Recombinant TgAMA-1 and various fragments of TgAMA-1 have been expressed in E. coli, but Western blotting with the conformation-sensitive MAb B3.90 suggested that these recombinant fragments were incorrectly folded. Proper folding of recombinant protein is more likely to be obtained in eukaryotic cell expression systems. To this end, we have recently expressed recombinant TgAMA-1 in insect cells. Using conventional molecular genetic techniques, Toxoplasma AMA-1 coding sequence corresponding to the signal peptide, ectodomain, and the transmembrane domain (amino acid residues 1-473) was amplified from cDNA and ligated into pIZ/V5-His(Invitrogen) in frame with both V5 and His eptiope tags. PIZ/V5-His encodes a Zeocin™ resistance selectable marker gene and the promoter, OpIE2, which drives constitutive expression of the inserted gene. The construct was transformed into E. coli and plasmid DNA was isolated from antibiotic resistant colonies. The presence of AMA-1 in pIZ/V5-His was confirmed by PCR, restriction digest analysis and sequencing. High Five™ cells were transfected with pIZ/AMA-1/V5-His and stable expression was indicated by Zeocin™ resistance. Antibiotic-resistant insect cell lines were cloned either by limiting dilution or by aspirating foci; AMA-1 expression was assayed by indirect immunofluorescence microscopy using monoclonal antibody B3.90 and an Alexa 488-conjugated secondary antibody. Recombinant TgAMA-1 expression in insect cells was detected with mAb B3.90.
- References
-
- [1] Wan K L, Carruthers V B, Sibley L D, Ajioka J W. Molecular characterisation of an expressed sequence tag locus of Toxoplasma gondii encoding the micronemal protein MIC2. Mol Biochem Parasitol 1997;84:203-14.
- [2] Carruthers V C, Giddings O K, Sibley D L. Secretion of micronemal proteins is associated with Toxoplasma invasion of host cells. Cellular Microbiology 1999;1:225-235.
- [3] Ward G E, Carey K L. 96-Well Plates Providing High Optical Resolution for High-throughput, Immunofluorescence-based Screening of Monoclonal Antibodies Against Toxoplasma gondii. J. Immunol. Meth. 1999;230:11-18.
- [4] Carruthers V B, Sibley L D. Mobilization of intracellular calcium stimulates microneme discharge in Toxoplasma gondii. Mol Microbiol 1999;31:421-8.
- [5] Roos D S, Donald R G, Morrissette N S, Moulton A L. Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii In: Methods in Cell Biology. 45, 1994; 27-63.
- [6] Carey K L, Donahue C G, Ward G E. Identification and molecular characterization of GRA8, a novel, proline-rich, dense granule protein of Toxoplasma gondii. Mol Biochem Parasitol 2000;105:25-37.
- [7] Church W R, Brown S A, Mason A B. Monoclonal antibodies to the amino- and carboxyl-terminal domains of ovotransferrin. Hybridoma 1988;7:471-84.
- [8] Harlow E, Lane D. Antibodies: A Laboratory Manual, Cold Spring Harbor: Cold Spring Harbor Laboratory, 1988.
- [9] Eng J K, McCormick A L, Yates J R I. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. Journal of the American Society of Mass Spectrometry 1994;5:976-989.
- [10] Chittum H S, Lane W S, Carlson B A, Roller P P, Lung F D, Lee B J, Hatfield D L. Rabbit beta-globin is extended beyond its UGA stop codon by multiple suppressions and translational reading gaps. Biochemistry 1998;37:10866-70.
- [11] Bercovici T, Gitler C. 5-[125I]Iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Biochemistry 1978;17:1484-9.
- [12] Hodder A N, Crewther P E, Matthew M L, Reid G E, Moritz R L, Simpson R J, Anders R F. The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem 1996;271:29446-52.
- [13] Brydges S D, Sherman G D, Nockemann S, Loyens A, Daubener W, Dubremetz J-F, Carruthers V B. Molecular Characterization of TgMIC5, a proteolytically processed antigen secreted from the micronemes of Toxoplasma gondii. Molecular and Biochemical Parasitology (in press).
- [14] Carruthers V B, Sherman G D, Sibley L D. The Toxoplasma adhesive protein MIC2 is proteolytically processed at multiple sites by two parasite-derived proteases. Journal of Biological Chemistry 2000;275:14346-14353.
- [15] Carruthers V B, Moreno S N, Sibley L D. Ethanol and acetaldehyde elevate intracellular [Ca2+] and stimulate microneme discharge in Toxoplasma gondii. Biochem J 1999;342:379-86.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
- All references, including patent documents, disclosed herein are incorporated by reference in their entirety.
Claims (20)
1. An isolated TgAMA-1 polypeptide molecule comprising an antigenic fragment of the polypeptide sequence set forth as amino acids SEQ ID NO:1.
2. A fusion protein comprising the antigenic polypeptide of claim 1 .
3. An isolated TgAMA-1 nucleic acid molecule selected from the group consisting of:
(a) a fragment of the nucleotide sequence set forth as nucleotides 1-2507 of SEQ ID NO:2 between 12 and 2506 nucleotides in length, and
(b) complements of (a),
wherein the fragment encodes the isolated polypeptide of claim 1 .
4. An expression vector comprising the isolated nucleic acid sequence of claim 3 operably linked to a promoter.
5. An expression vector comprising an isolated nucleic acid molecule of SEQ ID NO:2. operably linked to a promoter.
6. A host cell transformed or transfected with the expression vector of claim 4 .
7. A transgenic non-human animal comprising the expression vector of claim 4 .
8. The transgenic non-human animal of claim 7 , wherein the animal expresses a variable level of TgAMA-1.
9. The transgenic non-human animal of claim 7 , wherein the animal expresses an antigenic fragment of SEQ ID NO:1.
10. A composition comprising the isolated TgAMA-1 polypeptide of claim 1 and an adjuvant.
11. A composition comprising TgAMA-1 or a functionally active variant thereof, and an adjuvant.
12. A method for immunizing a subject comprising
administering to the subject an effective amount for immunizing the subject of a composition of claim 10 .
13. The method of claim 12 , wherein the subject is at risk of infection from Toxoplasma gondii.
14. A TgAMA-1 binding polypeptide that selectively binds to the isolated TgAMA-1 polypeptide of claim 1 .
15. The TgAMA-1 binding polypeptide of claim 14 , wherein the binding polypeptide is an antibody or antigen-binding fragment of an antibody.
16. The TgAMA-1 binding polypeptide of claim 15 , wherein the antibody or antigen-binding fragment specifically binds to a region comprising about 12 or more cysteine residues of the isolated polypeptide of claim 1 .
17. The TgAMA-1 binding polypeptide of claim 14 , wherein the binding polypeptide blocks entry of Toxoplasma parasite into a cell.
18. An isolated anti-idiotype antibody that selectively binds to the TgAMA-1 binding polypeptide of claim 14 .
19. A method for reducing the likelihood of or treating a toxoplasma infection, comprising:
administering to a subject in need of such treatment, an effective amount of a TgAMA-1 binding polypeptide of claim 14 to treat the toxoplasma infection.
20. The composition of claim 10 , wherein the composition is a proteosome vaccine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/089,047 US20050210535A1 (en) | 2000-11-09 | 2005-03-24 | Toxoplasma gondii apical membrane antigen-1 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24787000P | 2000-11-09 | 2000-11-09 | |
US10/039,770 US6902926B1 (en) | 2000-11-09 | 2001-11-09 | Toxoplasma gondii apical membrane antigen-1 |
US11/089,047 US20050210535A1 (en) | 2000-11-09 | 2005-03-24 | Toxoplasma gondii apical membrane antigen-1 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/039,770 Continuation US6902926B1 (en) | 2000-11-09 | 2001-11-09 | Toxoplasma gondii apical membrane antigen-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050210535A1 true US20050210535A1 (en) | 2005-09-22 |
Family
ID=34622401
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/039,770 Expired - Fee Related US6902926B1 (en) | 2000-11-09 | 2001-11-09 | Toxoplasma gondii apical membrane antigen-1 |
US11/089,047 Abandoned US20050210535A1 (en) | 2000-11-09 | 2005-03-24 | Toxoplasma gondii apical membrane antigen-1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/039,770 Expired - Fee Related US6902926B1 (en) | 2000-11-09 | 2001-11-09 | Toxoplasma gondii apical membrane antigen-1 |
Country Status (1)
Country | Link |
---|---|
US (2) | US6902926B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030113822A1 (en) * | 2001-05-22 | 2003-06-19 | President And Fellows Of Harvard College For Inventors Westwood And Mitchison | Identification of anti-protozoal agents |
US20050089867A1 (en) * | 2002-03-21 | 2005-04-28 | Nicola Gargano | Antigen fragments for the diagnosis of toxoplasma gondii |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6902926B1 (en) * | 2000-11-09 | 2005-06-07 | University Of Vermont And State Agricultural College | Toxoplasma gondii apical membrane antigen-1 |
DK1664097T3 (en) * | 2003-09-14 | 2010-03-29 | Univ Utrecht Holding Bv | Piroplasmid vaccine |
KR101335203B1 (en) | 2010-03-26 | 2013-11-29 | 숙명여자대학교산학협력단 | Peptides for Promotion of Angiogenesis and the use thereof |
CN104922696B (en) * | 2015-04-03 | 2019-01-29 | 延边大学 | Prevent the vaccine and its preparation method and application of neospora and arch insect infection simultaneously |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912143A (en) * | 1996-12-27 | 1999-06-15 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a human mage protein homolog |
US6392014B1 (en) * | 1992-06-15 | 2002-05-21 | Marie-France Cesbron | Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications |
US6902926B1 (en) * | 2000-11-09 | 2005-06-07 | University Of Vermont And State Agricultural College | Toxoplasma gondii apical membrane antigen-1 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5101017A (en) | 1987-04-06 | 1992-03-31 | New York Blood Center, Inc. | Antibodies for providing protection against P. vivax malaria infection |
US6066623A (en) | 1993-11-23 | 2000-05-23 | The United States Of America As Represented By The Secretary Of The Navy | Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines |
US6120770A (en) | 1997-09-12 | 2000-09-19 | University Of Notre Dame Du Lac | Plasmodium proteins useful for preparing vaccine compositions |
-
2001
- 2001-11-09 US US10/039,770 patent/US6902926B1/en not_active Expired - Fee Related
-
2005
- 2005-03-24 US US11/089,047 patent/US20050210535A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6392014B1 (en) * | 1992-06-15 | 2002-05-21 | Marie-France Cesbron | Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications |
US5912143A (en) * | 1996-12-27 | 1999-06-15 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a human mage protein homolog |
US6902926B1 (en) * | 2000-11-09 | 2005-06-07 | University Of Vermont And State Agricultural College | Toxoplasma gondii apical membrane antigen-1 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030113822A1 (en) * | 2001-05-22 | 2003-06-19 | President And Fellows Of Harvard College For Inventors Westwood And Mitchison | Identification of anti-protozoal agents |
US7067315B2 (en) * | 2001-05-22 | 2006-06-27 | President And Fellows Of Harvard College | Identification of anti-protozoal agents |
US20050089867A1 (en) * | 2002-03-21 | 2005-04-28 | Nicola Gargano | Antigen fragments for the diagnosis of toxoplasma gondii |
US7176286B2 (en) * | 2002-03-21 | 2007-02-13 | Kenton S.R.L. | Antigen fragments for the diagnosis of Toxoplasma gondii |
US20070141076A1 (en) * | 2002-03-21 | 2007-06-21 | Kenton S.R.I. | Antigen fragments for the diagnosis of Toxoplasma gondii |
Also Published As
Publication number | Publication date |
---|---|
US6902926B1 (en) | 2005-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2224113T5 (en) | ANTIGEN POLYPEPTIDE ASSOCIATED WITH MELANOMA, EPITHOPOS OF THE SAME AND VACCINES AGAINST MELANOMA. | |
AU2002367594B8 (en) | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies | |
Wang et al. | Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum | |
US20050210535A1 (en) | Toxoplasma gondii apical membrane antigen-1 | |
JP2008510464A (en) | Compositions and methods for the treatment and diagnosis of lung cancer | |
JP2012505212A (en) | Methods and compositions relating to chlamydia antigens for the diagnosis and treatment of chlamydia infections and diseases | |
US6641815B2 (en) | Sequestrin | |
Pearce et al. | Three major surface antigens of Schistosoma mansoni are linked to the membrane by glycosylphosphatidylinositol. | |
JPH01131125A (en) | Specific discharge-secretion antigen of toxoplasma gondii, its developed product, production thereof, and doagnostic and preventive use thereof | |
WO2002070542A2 (en) | Band 3 antigenic peptides, malaria polypeptides and uses thereof | |
JP2004508812A (en) | Compositions and methods for treatment and diagnosis of breast cancer | |
AU2009227821A1 (en) | GBS Toxin Receptor | |
JP4568500B2 (en) | Compositions and methods for the treatment and diagnosis of lung cancer | |
Stanley Jr et al. | Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African green monkey | |
US7897355B2 (en) | Gene expressed in prostate cancer and methods of use | |
WO2003097679A1 (en) | Cystic echinococcosis protein and uses therefor | |
US7273709B2 (en) | Detection of sarcocystis neurona | |
JP2003520594A (en) | Sperm-specific protein | |
US20090304702A1 (en) | Gene expressed in prostate cancer and methods of use | |
CZ20013268A3 (en) | Novel polypeptides and polynucleotides | |
BR112021000312A2 (en) | VACCINE, PEPTIDES, POLYPEPTIDE, POLYNUCLEOTIDE, VACCINE VECTOR, METHOD OF TREATING OR PREVENTING MAP INFECTION OR THE CONDITION OR SYMPTOM ASSOCIATED WITH MAP AND KIT INFECTION | |
JPH06505865A (en) | Cloning and expression of Toxoplasma gondii protein antigens | |
JP4446647B2 (en) | Babesiacanis vaccine | |
US20220072115A1 (en) | Malaria antigens on the surface of erythrocytes and merozoites and protective antibodies | |
AU2005239640B2 (en) | GBS Toxin Receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WARD, GARY E.;CONANT, CAROLYN G.;REEL/FRAME:016325/0795;SIGNING DATES FROM 20050426 TO 20050606 |
|
AS | Assignment |
Owner name: MCGILL UNIVERSITY & HEALTH CENTRE, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARD, BRIAN;REEL/FRAME:016669/0314 Effective date: 20050809 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |